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“…e ti senti una favola, 
e ti sembra che tutta la vita 
 non è solamente retorica, 
ma sostanza purissima, 
che ti nutre le cellule, 
e ti fa venir voglia di  
vivere fino all'ultimo attimo…” 
(L. Jovanotti “Terra degli Uomini”) 
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Abstract. 
   Several neuroblastoma (NBL) susceptibility loci located in diverse genes 
(LINC00340, BARD1, LMO1, DUSP12, HSD17B12, DDX4, IL31RA, HACE1 and 
LIN28B) have been identified by genome-wide association studies (GWAS). The 
replication of association studies are mandatory to validate and comprehensively 
evaluate the impact of the identified NBL variants on disease risk and phenotype. 
To this purpose, during my PhD program I have genotyped in an Italian 
population 14 single nucleotide polymorphisms (SNPs), that have already been 
associated with NBL in European Americans. All NBL susceptibility genes 
replicated in the Italian dataset except for two of them, and the most significant 
SNP was rs6435862 in BARD1. Interestingly, BARD1 showed an additional and 
independent SNP association (rs7585356). This variant also influenced BARD1 
mRNA expression in LCLs and NBL cell lines. Moreover, a cumulative effect of risk 
variants on NBL risk and development of high-risk phenotype was observed in a 
dose-dependent manner. These results provide further evidence that the risk loci 
identified in GWAS contribute to NBL susceptibility in distinct populations and 
strengthen the role of BARD1 as major genetic contributor to NBL risk.  
   Recent studies have demonstrated a role for interleukin(IL)-6, a pro-
inflammatory cytokine, in progression and development of diverse cancers. 
Moreover, it has been demonstrated that the SNP rs1800795 in IL-6 promoter is 
associated with inferior clinical outcomes in patients with high-risk NBL. In 
particular, the major allele is reported as associated with lower survival. Thus, it 
has been analyzed an Italian population to validate these data. The results 
showed that the SNP was not implicated in susceptibility to NBL development 
while the minor allele is significantly associated with a reduction of the overall 
survival, advanced stage, and high-risk phenotype. Moreover, the analysis of 
expression indicate the minor allele as correlated with increased level of IL-6 
expression. Kaplan-Meier analysis demonstrated that high levels of IL-6 were 
associated with poor outcome. These findings indicate that the biological effect of 
this SNP in relation to promotion of cancer progression is consistent with the 
observed decreased survival time. 
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Background. 
Clinical of neuroblastoma. 
   NBL is a neuroendocrine tumor, arising from any neural crest 
element of the sympathetic nervous system. About half of NBLs arise in 
the adrenal medulla, while the other half arise in paraspinal 
sympathetic ganglia in the chest or abdomen or in pelvic ganglia. NBL 
is an important clinical problem, accounting for more than 7% of 
malignancies in children and around 15% of pediatric oncologic deaths 
(Gurney JG et al. 1997).   
   NBL is diagnosed at a median age of about 17 months and it is the 
most common cancer diagnosed during the first year of life. The 
incidence of NBL is 10.2 cases per million children under 15 years of 
age (London WB et al. 2005; Linet MS et al. 1999).  
   Primary tumors in the neck or upper chest can cause Horner's 
syndrome (ptosis, miosis, and anhidrosis). Tumors along the spinal 
column can expand through the intraforaminal spaces and can cause 
cord compression, with resulting paralysis. Although many lower-stage 
NBLs are encapsulated and can be surgically excised with little chance 
of complications, higher-stage tumors often infiltrate local organ 
structures, surround critical nerves and vessels such as the celiac axis, 
and are largely unresectable at the time of diagnosis. NBLs typically 
metastasize to regional lymph nodes and to the bone marrow by 
means of the hematopoietic system. Tumor cells metastatic to marrow 
can infiltrate cortical bone. NBLs can metastasize also to the liver, most 
notably in patients with stage 4S tumors, in whom involvement can be 
extensive; however, transient and complete regression often occurs 
with no intervention other than supportive care. 
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Indeed, NBL is an heterogenous tumor with the highest rate of 
spontaneous regression of all human cancers. However, most children 
of more than 1 year of age have extensive or metastatic disease with 
poor prognosis at diagnosis and around 50% of the patients show 
resistance to chemotherapy. This clinical heterogeneity is due to the 
complex genomic abnormalities acquired in tumor cells. 
   The International Neuroblastoma Staging System (INSS) stratifies 
NBL according to the anatomical presence at diagnosis (Brodeur GM et 
al. 1988 and 1993)(Figure 1): 
 Stage 1: localized tumor confined to the area of origin; 
 Stage 2A: unilateral tumor with incomplete gross resection; 
 Stage 2B: unilateral tumor with complete or incomplete gross 
resection; 
 Stage 3: tumor infiltrating across midline with or without 
regional lymphnode involvement; 
 Stage 4: dissemination of tumor to distant lymphnodes, bone 
marrow, bone, liver or other organs except as defined by Stage 
4S; 
 Stage 4S: localized primary tumor in infants younger than 1 
year, with dissemination limited to liver, skin, or bone marrow. 
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   According to Brodeur GM et al. (1993), the stage of disease, as 
formulated in the INSS, can also be considered a surrogate marker of 
the tumor burden and underlying tumor biology. Moreover, because of 
the complexity of the disease, age at diagnosis, clinical stage based on 
the INSS and tumor histology are important factors in predicting the 
outcome of NBL and these information can be useful in the selection of 
therapy (Maris JM et al. 2007). 
   At the extreme ends of the spectrum with respect to age and stage of 
disease, there is little controversy concerning risk classification. Older 
children with stage 4 (metastatic) disease are at high risk for death 
from refractory disease. In contrast, infants with localized tumors are 
almost always cured, often without cytotoxic therapy. For patients who 
fall between these extremes, however, it has been difficult to reach a 
consensus, owing to both the relative rarity of the condition and the 
evolving nature of molecular diagnostics. To address this issue of 
classification, Cohn and Pearson (2009) conducted a study that led to 
the development of a new tumor staging system that divides localized 
tumors into two groups on the basis of the presence or absence of 
2b
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Figure 1. Stratification of NBL patients according to INSS. 
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rigorously defined surgical risk factors (Cecchetto G et al. 2005; 
Monclair T et al. 2009) and an age cutoff point of 18 months was 
proposed. An International Neuroblastoma Risk Group (INRG) 
classification system with a total of 16 statistically distinct risk groups 
was proposed. This classification is based on the assessment of 13 
potential prognostic factors. Four broad categories - very low risk, low 
risk, intermediate risk, and high risk - were proposed in terms of 5-
year event-free survival rates of >85%, >75 to ≤85%, ≥50 to ≤75%, and 
<50%, respectively, on the basis of the analysis of age at diagnosis, 
INRG tumor stage, histologic category, grade of tumor differentiation, 
DNA ploidy, and copy-number status at the MYCN oncogene locus and 
at chromosome 11q.  
   Tumor-derived genomic information has been used since the 1980s 
to predict the course of newly diagnosed NBLs, with the discovery that 
the MYCN oncogene is the target of the extremely high-level 
amplifications at chromosome band 2p24 observed in about 20% of 
NBL cases. Because MYCN amplification has a profound effect on the 
clinical outcome, it is routinely used as a biomarker for treatment 
stratification (Schwab M et al. 1983; Brodeur GM et al. 1984; Seeger RC 
et al. 1985). Since the initial discovery of MYCN, many prognostic 
biomarkers have been proposed for NBL, the most intensely studied of 
which include histopathological classification, the tumor-cell DNA 
index (ploidy), and specific recurrent segmental chromosomal 
aberrations. More recently, microarray-based technologies have 
permitted the detailed dissection of the NBL genome and 
transcriptome, and several outstanding studies indicate that patterns 
of DNA-based or RNA-based aberrations have substantial predictive 
power (Oberthuer A et al. 2006; Asgharzadeh S et al. 2006; Ohira M et 
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al. 2005; Wei JS et al. 2004; Spitz R et al. 2006; Janoueix-Lerosey I et al. 
2009).  
   Taken together, the available data suggest that DNA copy-number 
aberrations fall into two broad prognostic categories: whole-
chromosome gains that result in hyperdiploidy and are associated with 
a favorable prognosis and segmental chromosomal aberrations, such 
as amplification of MYCN and regional loss or gain of chromosomal 
material, that tend to be associated with a worse outcome (Janoueix-
Lerosey I et al. 2009) (Figure 2).    
 
 
Genetics of neuroblastoma. 
   The aetiology of NBL is unknown. A subset of patients inherits a 
genetic predisposition to NBL and NBLs can be classified into subtypes 
that are predictive of clinical behavior based on the patterns of genetic 
change. 
   The genetic aberration most consistently associated with poor 
outcome in NBL is the genomic amplification of MYCN (Brodeur GM et 
al. 1986 and 1987). MYCN amplification occurs in roughly 20% of 
primary tumors and is strongly correlated with advanced stage disease 
Figure 2. Classification of NBLs according to INRG. 
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and treatment failure (Brodeur GM et al. 1984; Seeger RC et al. 1985) 
(Figure 3). 
 
 
   Deletions of the short arm (p) of chromosome(chr) 1 can be 
identified in 25–35% of NBLs. These deletions correlate not only with 
MYCN amplification, but also with advanced stage of the disease 
(White PS et al. 1995; Gehring M et al. 1995; Martinsson T et al. 1995; 
White PS et al. 2001). However, the gene or genes within chr1p 
involved in the pathogenesis of NBL have not been identified yet. 
Whether the loss of heterozygosity due to deletion of alleles from 
chr1p is an independent indicator of prognosis remains controversial. 
However, evidence suggests that allelic loss at chr1p36 predicts an 
increased risk of relapse in patients with localized tumors (Gehring M 
et al. 1995; Caron H et al. 1996; Maris JM et al. 2000; Spitz R et al. 
2002).  
   Allelic loss of the long arm (q) of chr11 is present in 35–45% of 
primary tumors (Guo C et al. 1999; Plantaz D et al. 2001; Spitz R et al. 
2003). This genomic aberration is rarely seen in tumors with MYCN 
amplification, yet remains highly associated with other high-risk 
features.  
Figure 3. MYCN amplification in NBL. 
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   A gain of additional chr17q copies, often through unbalanced 
translocation with chr1 or chr11, can also correlate with a more 
aggressive phenotype suggesting that a dosage effect of one or more 
genes provides a selective advantage (Bown N et al. 1999; 
Schleiermacher G et al. 2004). 
   Other frequently detected structural genetic alterations in NBL were 
reported, including allelic loss of genetic material located on chr3p, 4p, 
9p, 14q, 16p and 19q, as well as segmental gains of 1q, 5q and 18q 
(Schwab M et al. 2003) and most of these markers have been 
associated with unfavorable features of the disease. Furthermore, copy  
number changes of whole chromosomes are also commonly observed 
in NBL, and are closely associated with the ploidy of the tumors 
(Brodeur GM 2003). In most cases, karyotypes of NBL cells are either 
in the diploid ('near-diploid') or hyperdiploid ('near-triploid') range. A 
near-triploid DNA content has been shown to be associated with 
favorable features such as stages 1-3 and 4S, a younger age at 
diagnosis, a lack of structural chromosomal aberrations and a more 
favorable outcome of the patient (Spitz R et al. 2006; Look AT et al. 
1991; Kaneko Y et al. 1990). 
   Recently, genome-wide association studies (GWAS) focusing on 
single nucleotide polymorphisms (SNPs) provided the basis for the 
identification of activating mutations in the anaplastic lymphoma 
kinase (ALK) oncogene. These mutations appear to be responsible for 
most of the rare cases of hereditary NBL, and might also be relevant for 
a smaller fraction of the 6-9% of sporadic tumors (Chen Y et al. 2008; 
Janoueix-Lerosey I et al. 2008; Mossè YP et al. 2008). Interestingly, an 
even higher percentage of primary NBL (20-25%) present copy 
number increases at the ALK locus on chr2p23. Together with reports 
on elevated ALK gene-expression levels in aggressively growing NBL, 
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these findings strongly support an important role of this oncogene for 
NBL tumorigenesis (Wang Q et al. 2006; Oberthuer A et al. 2008; 
Osajima-Hakomori Y et al. 2005).  
   Prior to this revelation, the PHOX2B transcription factor, a homeobox 
gene functioning as an important regulator of normal autonomic 
nervous system development, was shown to be mutated in a small 
subset (~2%) of neuroblastic tumors (Mossè YP et al. 2004; Trochet D 
et al. 2004; van Limpt V et al. 2004). 
   The figure 4 illustrates the most common genomic aberrations in 
NBL. 
 
 
 
 
 
 
Figure 4. Genomic aberrations in NBL. 
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Genome Wide Association Studies (GWAS) of neuroblastoma. 
   Very little is known about elements predisposing to NBL as no 
specific environmental factors have been identified (Olshan et al. 
1999_1 and 1999_2). The predisposition seems to be genetically 
heterogeneous. So, the tumor onset could be due to the presence of 
more alterations. This suggests that NBL is a genetic complex disease 
and its tumorigenesis could be the result of different genetic 
alterations. 
   A classical human genetic association study is based on a biological 
hypothesis. Indeed, this kind of study is used to test for a correlation 
between disease status and genetic variation to identify candidate 
genes or genome regions that contribute to a specific disease (Figure 
5).  
 
 
  
  In contrast to this method, GWAS is a method free-of-hypothesis that 
investigates the whole genome. GWAS is an examination of many 
common genetic variants in different individuals to see if any variant is 
Figure 5. Human Genetic Association Study. 
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associated with a trait. Generally, GWAS focus on associations between 
SNPs and disease. The approach of GWAS is the case-control setup 
which compares a healthy control group and a case group affected by a 
disease. The SNPs genotyped typically are 550K or a million (Figure 6). 
 
 
 
For every SNPs on the chip is evaluated if the allele frequency is 
significantly altered between the two populations studied.  
   In such setups, the fundamental parameters are the ORs and the p-
value for the significance of the ORs (generally calculated by chi-
squared test). Subsequently, it is created a “Manhattan plot” that shows 
the negative logarithm of the p-value as a function of genomic location. 
In this way, the most significant associated SNPs will be out on the plot 
(Figure 7). The p-value threshold for significance is corrected for 
multiple testing issues and the exact threshold is typically very low 
(about 10-7 -10-8) because of the millions of tested SNPs. 
 
Figure 6. GWAS approach. 
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   In the last years GWAS have been performed to study NBLs and it has 
been demonstrated that common variants in DNA predispose to NBL 
onset. Indeed, three intronic SNPs in the predicted gene FLJ22536 
(chr6p22) have been associated to NBL development and poor 
prognosis  (Maris et al. 2008).  
   Moreover, a case/control study has demonstrated that BARD1 gene is 
a new gene of susceptibility to NBL high risk (Capasso et al. 2009). 
BARD1 is a tumor-suppressor gene that herodimerizes with BRCA1 
(Baer et al. 2002; Simons et al. 2006) playing an active role in tumor 
suppression. In literature, BARD1 is reported as necessary for 
progression in the phase S of the cell cycle and as necessary for contact 
inhibition in mammal cells. Moreover, BARD1 is involved in the 
apoptotic response mediated by p53 in genotoxic stress (Figure 8) 
(Irminger-Finger et al. 2001; Jefford et al. 2004).  
 
Figure 7. Manhattan plot (adapted from Maris et al. 2008) 
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   BARD1 gene is polymorphic and some of its SNPs, in particular six 
intronic SNPs, three non-synonymous SNPs and one SNP localized in 
the regulatory region of the gene, have been strongly associated with 
high risk NBL in the European American population (Capasso et al. 
2009). 
   Recently, another study has identified LMO1 as a NBL oncogene 
(Wang et al. 2011). LMO1 encodes a cysteine-rich transcriptional 
regulator. The SNP risk alleles and somatic copy number gains were 
associated with increased LMO1 expression in NBL cell lines and 
primary tumors, consistent with a gain-of-function role in 
tumorigenesis.  
   The SNP associations reported above were particularly enriched in 
the high-risk group, whereas, SNPs within dual specifity phosphatase 
12 (DUSP12), hydroxysteroid (17-beta) dehydrogenase 12 
(HSD17B12), DEAD (Asp-Glu-Ala-Asp) box polypeptide 4 (DDX4) and 
interleukin 31 receptor A (IL31RA) were enriched in the low-risk 
Figure 8. BARD1 role in death and survival pathways. 
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group. Additional SNPs within HECT domain and ankyrin repeat 
containing E3 ubiquitin protein ligase 1 (HACE1) and lin28 homolog B 
(C. Elegans) (LIN28B) have been found to be associated with NBL but 
not with disease phenotype (Diskin et al. 2012). 
   Other recent studies have demonstrated a role for IL-6, a pro-
inflammatory cytokine, in progression and development of multiple 
myeloma, colon cancer, melanoma, renal cancer, Hodgkin’s disease, 
non-Hodgkin’s lymphoma, prostate cancer, breast cancer (Heikkilä K et 
al. 2008). 
In particular, the increase of IL-6 has been associated to the up-
regulation of the expression of adhesion receptors on endothelial cells 
and to the production of growth factors. These events promoted the 
formation of favorable microenvironment for metastasis and suggested 
a role for IL-6 as a stimulator of metastasis (Hirano T 1997; Hutchins D 
et al. 1994). Moreover, it has been demonstrated that the peripheral 
blood levels of IL-6 correlated with NBL progression and development 
(Egler RA et al. 2008) and that IL-6 promoted growth and survival of 
NBL cells in the bone marrow (Ara T et al. 2009). Interestingly, the 
studies by Lagmay et al. (2009) reported the SNP rs1800795 (-174 
G>C) in IL-6 promoter as associated with inferior clinical outcomes in 
patients affected by high-risk NBL. 
   All these findings suggest a “common variant-common disease” 
model for NBL: the interaction of multiple genetic variations can 
influence the development of the disease. 
Model of neuroblastoma tumorigenesis. 
   The figure 9 shows a hypothetical model of NBL tumorigenesis based 
on germline mutations and common genetic variations associated to 
the disease. 
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   The model reports the number of co-occurring risk alleles in a child’s 
germline DNA along with the corresponding odds ratio (ORs) assuming 
an additive effect. The threshold for malignant transformation is set at 
an OR of 50. The blue line represents the typical child: the germline 
DNA presents only a small subset of risk alleles and thus the child is 
not at risk for developing the disease. 
   The green line shows a child with mutations within ALK or PHOX2B 
that is considered at risk for developing NBL. In presence of additional 
risk alleles, this child may become a familial NBL patients (black line), 
while, in absence of additional risk alleles, the child will be considered 
at risk but not develop the disease. 
   The red line shows a sporadic NBL patient that lacks mutations 
within ALK or PHOX2B likely requires the presence of 20 or more risk 
alleles before reaching the threshold for the malignant transformation.  
Figure 9. Graphical model of the genetics of NBL tumorigenesis. 
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Aims of the Study. 
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Aims of the Study. 
   The main objective of our study is to validate the identified GWAS 
NBL risk variants. To this purpose, I performed a case-control study to 
demonstrate that SNPs associated to NBL in European Americans are 
also associated to NBL in Italians. In particular, it has been assessed the 
association of NBL with 14 SNPs (rs6939340, rs4712653 located in 
LINC00340, rs6435862, rs3768716, rs7585356, rs2070094, 
rs2229571, rs1048108 located in BARD1, rs110419 and rs4758051 in 
LMO1, rs1027702 in DUSP12, rs11037575 in HSD17B12, rs2619046 in 
DDX4 and rs10055201 in IL31RA) (Capasso et al. 2013). The results of 
the Italian case-control study were compared to those of the European 
American GWAS composed of 1627 cases and 2575 controls (Nguyen 
le et al. 2011). I also replicated the SNP rs1800795 in IL-6 promoter 
found associated with negative prognosis in high-risk NBL patients 
(Lagmay et al. 2009). 
   The expected outcome for this study is to deliver to the research 
community a validated catalog of NBL susceptibility variants across the 
spectrum of allele frequencies and effect sizes, which could have 
implications in providing fundamental new insights into NBL 
tumorigenesis. All these tasks may help to identify the events 
responsible of NBL progression and development. 
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Materials and Methods. 
DNA samples used for the replication of GWAS-identified 
neuroblastoma risk loci. 
   This study consisted of 370 NBL patients collected through the Italian 
Neuroblastoma Group and 809 cancer-free controls of Italian origin. The 
population has been described in detail in our previous paper (Capasso et 
al. 2013).  
   Clinical and biological characteristics of the patients are shown in table 1.  
Samples were assigned into two risk groups (not high-risk and high-risk) 
based on the COG risk assignment.  
DNA samples used for the replication study on IL-6 promoter 
polymorphism. 
   The study consisted of 326 DNAs extracted from peripheral blood of NBL 
patients collected through the Italian Neuroblastoma Group and 511 DNAs 
from cancer-free controls of Italian origin (mean age 9.67 ± 5.41 year). 
Clinical and biologic characteristics of the patients are shown in table 2. 
Samples were assigned into two risk groups (not high-risk and high-risk) 
based on the COG risk assignment.  DNA samples have been described in 
full detail in our paper appended to the thesis (Totaro F et al. 
2013_submitted). 
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 Italians  
(N=370) 
Variable Number (%) 
Age  
>18 months 170 (46.8) 
< 18 months 193 (53.2) 
Unknown 7 
INSS Stage  
4 145 (40.2) 
1, 2, 3, 4S 216 (59.8) 
Unknown 9 
MYCN  
Amplified 80 (24.0) 
Not Amplified 254 (76.0) 
Unknown 36 
Risk  
High Risk 212 (57.3) 
Not High Risk 158 (42.7) 
Unknown - 
 
 
 
 
 
 
 
Table 1. Clinical characteristic of study samples for replication of GWAS. 
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  n  
Cases 326 
Controls 511 
Age 
 
> 18 months 152 
< 18 months 168 
Unknown 6 
Sex 
 
Males 178 
Females 141 
Unknown 7 
INSS stage 
 
Stage 1 + 2 103 
Stage 3 + 4 192 
Stage 4S 23 
Unknown 8 
Risk 
 
High-risk 144 
Not high-risk 182 
MYCN 
 
Amplified 73 
Not Amplified 221 
Unknown 32 
 
Table 2. Clinical characteristic of study samples for IL-6 SNP association. 
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SNPs selection and genotyping. 
   The SNPs selection and the genotyping methods are described precisely 
in our previous papers (Capasso et al. 2013; Totaro F et al. 
2013_submitted). 
Briefly, for the replication of GWAS-identified NBL risk loci, we selected 14 
genetic variants that have previously been associated with NBL in 
European American children. We included the two most significant SNPs 
identified in LINC00340 (intronic rs6939340, rs4712653) (Maris et al. 
2008), in BARD1 (intronic rs6435862, rs3768716) (Capasso et al. 2009), 
and in LMO1 (intronic rs110419 and intergenic rs4758051) (Wang et al. 
2011) as previously reported. In addition, we genotyped the putative 
functional variation rs7585356 located 3’ downstream of BARD1, and its 
coding variants rs2070094, rs2229571, and rs1048108 (Capasso et al. 
2009). We also analyzed four SNPs (intergenic rs1027702 near DUSP12, 
intronic rs11037575 in HSD17B12, rs2619046 in DDX4, and rs10055201 
in IL31RA) recently found to be associated with low-risk NBL (Nguyen le 
et al. 2011). The Italian DNA samples were genotyped by TaqMan assay or 
by Restriction Fragment Length Polymorphism (RFLP). 
   To test NBL risk variants cumulative effect, we also used genotype data 
of rs4336470 (HACE1) and rs17065417 (LIN28B) already demonstrated 
to be associated with NBL in this Italian case-control sample (Diskin et al. 
2012). 
   For the study of the polymorphism in IL-6 promoter, DNA samples were 
screened for the SNP rs1800795 using RFLP mapping to identify each 
patient’s genotype. The RFLP strategy is the same described by Lagmay et 
al. (2009). 
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In silico gene expression correlation analysis. 
 As described in our paper (Capasso et al. 2013), the influence of SNPs on 
gene expression was evaluated using two web tools, SNPexp v1.2 
(http://app3.titan.uio.no/biotools/tool.php?app=snpexp) (Holm et al. 2010) and 
Genevar v3.1.0 (http://www.sanger.ac.uk/resources/software/genevar/) (Yang et 
al. 2010).  
   SNPexp calculates correlation between HapMap genotypes and gene 
expression levels in LCLs using linear regression under an additive model. 
For this analysis, 198 unrelated HapMap3 subjects were chosen.  
   In Genevar, a linear regression (under an additive model) was used to 
calculate the SNP-gene expression correlations performing a Matched Co-
Twin Analysis. The expression and genotype data were obtained from 
LCLs of 170 individuals separate in two sets, Twin 1 (81 subjects) and 
Twin 2 (89 subjects). This analysis permits immediate replication and 
validation of the identified SNP-gene expression associations. 
   Also for IL-6 the SNP-gene expression correlation analysis, the influence 
of the SNP has been evaluated using SNPexp v1.2 
(http://app3.titan.uio.no/biotools/tool.php?app=snpexp). For this analysis, 198 
unrelated HapMap3 subjects were chosen. In addition, in silico analysis of 
IL-6 gene expression-outcome correlation has been performed. Two 
independent sets of normalized gene expression data and clinical 
annotations were downloaded from the website R2, microarray analysis 
and visualization platform (http://hgserver1.amc.nl/cgi-bin/r2/main.cgi): 
1) Versteeg dataset composed of 88 NBL samples; 
2) Seeger dataset composed of 102 NBL samples.  
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Genotyping of neuroblastoma cell lines. 
   For routine maintenance, cells were grown in RPMI 1640 complete 
media or DMEM complete media. 
   NBL cell lines were genotyped by direct sequencing for the HSD17B12-
SNP rs11037575 and for the BARD1-SNP rs7585356.  
   The isolation of genomic DNA and PCR strategy, including primers 
sequences, are reported in our previous paper (Capasso et al. 2013).  
Gene expression of neuroblastoma cell lines. 
  As reported in detail in our published paper (Capasso et al. 2013) RNA 
was isolated from NBL cell lines using the TRIzol reagent (Invitrogen Life 
Technologies). Two hundred ng of total RNA was reverse transcribed into 
cDNA using iScript cDNA Synthesis Kit (BIORAD). Quantitative RT-PCR 
(qRT-PCR) using Power SYBR Green PCR Master Mix (Applied Biosystems) 
was performed to evaluate the gene expression of HSD17B12 and BARD1. 
   Samples were amplified on an Applied Biosystems 7900HT Sequence 
Detection System and data collected and analyzed by 2^-Δct method. β-
actin gene was used as housekeeping gene. Primers overlapping the exon-
exon junction were used and they were specifically designed to detect the 
cDNA full lenght isoforms. 
IL-6 gene expression analysis in primary tumors. 
   RNA from 31 NBL tissues has been isolated using the TRIzol reagent 
(Invitrogen Life Technologies). Two thousand ng of total RNA was reverse 
transcribed into cDNA using iScript cDNA Synthesis Kit (BIORAD). To 
evaluate the gene expression of IL-6, quantitative real time PCR (qRT-PCR) 
was performed using Power SYBR Green Master Mix (Applied 
Biosystems). Samples were amplified on an Applied Biosystems 7900HT 
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Sequence Detection System and data were collected and analyzed by 2^-
Δct method. HPRT was used as housekeeping gene. Primers overlapping 
the exon-exon junction were used  and the primers for IL-6 were specific 
for the full length isoform (Totaro F et al. 2013_submitted).      
Statistical analysis. 
   The statistical analysis are reported in full detail in our previous paper 
(Capasso et al. 2013; Totaro F et al. 2013_submitted).  
   Briefly, for the replication of GWAS-identified NBL risk loci, Hardy-
Weinberg equilibrium (HWE) was evaluated. Two-sided chi-square tests 
were used to evaluate differences in the distributions of allele frequencies 
between all patients and controls, and only high-risk patients and controls. 
   ORs and 95% confidence intervals (CIs) were calculated to assess the 
relative disease risk conferred by a specific allele. We defined replication 
as a p-value of ≤0.05 with a consistent direction of association. We did not 
correct for multiple tests because the analyzed genes were previously 
reported associated to NBL in multiple independent datasets (Capasso et 
al. 2009; Latorre et al. 2012; Maris et al. 2008; Nguyen le et al. 2011; Wang 
et al. 2011).  
   To compare the differences in the mRNA expression levels between NBL 
cell lines stratified according to genotype Student’s t test was used. 
   Linkage disequilibrium (LD) and haplotype analysis were performed 
using the website tool SNAP v2.2 
(http://www.broadinstitute.org/mpg/snap/index.php) (Johnson et al. 2008) and 
Haploview v4.2 software (Barrett et al. 2005).  
   The cumulative effects of the independent significant risk loci on NBL 
initiation and phenotype have been assessed counting the number of risk 
alleles in each subject and modeling the summary variable categorically in 
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logistic regression analysis. This analysis was performed using IBM SPSS 
19.0 software.  
   Gene-gene interaction was tested using logistic regression additive 
model by adding an interaction term between the genotypes from all pair 
of SNPs investigated. This analysis was performed by PLINK software 
v1.06 (Purcell et al. 2007). 
   Also for the replication study on IL-6 promoter, HWE was evaluated 
using the goodness-of-fit chi-square test in control subjects. Two-sided 
chi-square tests were used to test for associations of the existence of 
polymorphism versus each other clinical factor, all patients, and only high-
risk patients. ORs and 95% CIs were calculated to assess the disease risk 
conferred by a specific allele or genotype.  
   Overall Survival (OS) was calculated by Kaplan-Meier method to 
generate survival curves which were compared using a log-rank test.  
   The Cox regression model was used to test for the independent 
predictive ability of the SNP after the adjustment for other significant 
factors: MYCN amplification, age, INSS stages. P-values of <0.05 were 
considered statistically significant. 
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Results and Discussion. 
  
34 
 
Results. 
Replication of GWAS-identified neuroblastoma risk loci. 
   The allele frequencies of all selected genetic variants among cases 
and controls and their association with NBL and high-risk phenotype 
are shown in table 3. 
   The observed genotype frequency among the control subjects was in 
agreement with HWE, except for rs2070094 (p<0.001). So this SNP was 
excluded  from further analyses. 
   In the population studied significant differences of allele distributions 
were observed for all SNPs except rs4758051 (LMO1), rs2619046 
(DDX4) and rs10055201 (IL31RA). SNP rs6435862 within BARD1 was 
the most significant (table 3, p=8.4x10-15).  
   In Italian children, all SNPs showed a pattern of association to NBL  
that is similar to that reported in European Americans (Capasso et al. 
2013).  Moreover, all SNPs of LINC00340 and BARD1, and one of LMO1 
were significantly associated with high-risk NBL both in Italians and in 
Americans (Capasso et al. 2013) (table 3). 
 
 
  
  
Table 3. Association of sixteen previously identified SNPs with NBL in Italian children.  
     
 
  
    
Italians 
      
SNP-gene expression 
associations    
SNP ID 
Chromosome 
band 
Function 
a
Allele 
Case 
genotypes 
High risk 
genotype
s 
Control 
genotype
s 
Case 
MAF 
(No.) 
High 
risk 
MAF     
(No.) 
Control 
MAF 
c
P 
c
OR 
(95% 
CI) 
d
P 
d
OR 
(95% 
CI) 
e
P  
HapM
ap 
f
P        
Twin1 
f
P         
Twin
2 
LINC00340  
rs6939340 
6p22 - A/G 
74, 
162,103 
29, 71, 48 
196, 390, 
175 
0.54 0.56 0.49 0.01 
1.25         
(1.04-
1.50) 
0.01 
1.37            
(1.06-
1.76) 
- - - 
LINC00340 
rs4712653 
6p22 - T/C 
78, 155, 
108 
31, 62, 57 
199, 376, 
197 
0.54 0.59 0.50 0.05 
1.20         
(1.00-
1.44) 
5.3 x 
10-3 
1.43        
(1.11-
1.83) 
- - - 
BARD1 
rs6435862 
2q35 Intronic T/G 
120, 155, 
69 
49, 67, 33 
423, 312, 
49 
0.43 0.45 0.26 
8.4 x 
10-15 
2.10          
(1.73- 
2.53) 
1.2 x 
10-10 
2.28        
(1.76-
2.94) 
0.50 
4.8 x 
10-6 
3.0 x 
10-4 
BARD1 
rs3768716 
2q35 Intronic A/G 
155, 153, 
50 
60, 74, 20 
473, 289, 
45 
0.35 0.37 0.23 
2.9 x 
10-9 
1.78          
(1.50-
2.16) 
6.3 x 
10-7 
1.91         
(1.48-
2.48) 
0.16 
5.0 x 
10-4 
4.0 x 
10-4 
BARD1 
rs7585356 
2q35 
3' 
downstream 
G/A 
204, 120, 
19 
94, 51, 7 
370, 305, 
94 
0.23 0.21 0.32 
2.0 x 
10-5 
0.63            
(0.51-
0.78) 
2.2 x 
10-4 
0.57        
(0.43-
0.77) 
3.0 x 
10-4 
1.0 x 
10-4 
7.7 x 
10-8 
BARD1 
rs2070094 
2q35 
exon 6 
(Val507Met) 
G/A 219, 83, 24 103, 33, 9 
419, 247, 
109 
0.20 0.18 0.30 
1.8 x 
10-6 
0.59          
(0.47- 
0.73) 
2.0 x 
10-5 
0.50        
(0.36-
0.68) 
- - - 
BARD1  
rs2229571 
2q35 
exon 4 
(Arg378Ser) 
G/C 
165, 124, 
61 
74, 53, 24 
238, 363, 
208 
0.35 0.33 0.48 
7.1 x 
10-9 
0.58         
(0.49 
- 
0.70) 
2.5 x 
10-6 
0.54        
(0.42-
0.70) 
- 
1.0 x 
10-3 
6.8 x 
10-6 
BARD1 
rs1048108 
2q35 
exon 1 
(Pro24Ser) 
C/T 156, 98, 28 69, 39, 10 
296, 355, 
99 
0.27 0.25 0.37 
4.5 x 
10-5 
0.64          
(0.52-
0.79) 
3.9 x 
10-4 
0.57        
(0.42-
0.78) 
- - - 
LMO1  
rs110419 
11p15 Intronic G/A 84, 152, 87 36, 62, 39 
271, 370, 
133 
0.50 0.51 0.41 
5.0 x 
10-5 
1.46          
(1.21-
2.0 x 
10-3 
1.50        
(1.16-
0.24 0.03 0.60 
3
5 
  
1.76) 1.94) 
LMO1 
rs4758051 
11p15 Intergenic A/G 
114, 156, 
70 
47, 72, 23 
246, 405, 
141 
0.44 0.42 0.43 0.94 
1.00          
(0.84-
1.21) 
0.57 
0.93           
(0.72-
1.20) 
0.34 0.20 0.22 
DUSP12 
rs1027702 
1q23.3 Intergenic C/T 
141, 156, 
52 
61, 67, 22 
258, 385, 
128 
0.37 0.37 0.42 0.05 
0.83          
(0.69-
1.00) 
0.14 
0.83        
(0.64-
1.06) 
4.0 x 
10-7 
0.42 0.27 
HSD17B12 
rs11037575 
11p11.2 Intronic T/C 
123, 168, 
52 
52, 74, 21 
322, 379, 
84 
0.40 0.39 0.35 0.03 
1.23          
(1.02-
1.47) 
0.13 
1.22              
(0.94-
1.57) 
1.1 x 
10-8 
7.2 x 
10-6 
2.0 x 
10-4 
DDX4  
rs2619046 
5p15.2-p13.1 Intronic G/A 
180, 130, 
25 
78, 60, 8 
456, 300, 
44 
0.27 0.26 0.24 0.19 
1.15          
(0.93-
1.41) 
0.52 
1.10        
(0.83-
1.46) 
0.30 0.24 0.69 
IL31RA 
rs10055201 
5p15.2-p13.1 Intronic A/G 
199, 123, 
20 
90, 54, 7 
475, 264, 
36 
0.24 0.23 0.22 0.26 
1.13        
(0.91-
1.40) 
0.75 
1.05        
(0.78-
1.41) 
0.68 0.26 0.41 
HACE1 
rs4336470 
6q16.3 Intronic C/T 
176, 136, 
38 
63, 68, 18 
348, 329, 
103 
b0.30 0.35 b0.34 b0.06 
b0.71          
(0.52-
0.97) 
0.84 
1.03        
(0.79-
1.33) 
0.02 0.23 0.60 
LIN28B 
rs17065417 
6q21 Intronic A/C 298, 48, 5 126, 22, 2 
600, 155, 
8 
b0.08 0.09 b0.11 b0.03 
b0.83        
(0.68-
1.00) 
0.75 
0.75        
(0.49-
1.16) 
- 0.92 0.14 
         a
 Major/minor Alleles; Italians: 370 cases and 809 controls; 
b
 Data as reported in Diskin et al. 2012; 
c
 P-values and ORs from comparison of Case versus Control; 
d
 P-values 
and ORs from comparison of High risk versus Control; 
e
 P-values from SNP-gene expression correlation using 198 unrelated HapMap subjects (SNPexp web tool); 
f
 P-values 
from SNP-gene expression correlation using 170 subjects (Genevar web tool). 
3
6 
 37 
 
   Subsequently it has been  tested for SNP-gene expression 
associations at all 14 SNPs and at 2 previously reported SNPs (Diskin et 
al. 2012). The analysis of gene expression variation using genome-wide 
expression arrays from LCLs of 198 unrelated HapMap individuals 
demonstrated that SNPs rs7585356 (BARD1), rs1027702 (DUSP12), 
rs4336470 (HACE1) and rs11037575 (HSD17B12) affected expression 
of the respective genes (table 3). These results were confirmed in 170 
additional LCLs only for rs7585356 (BARD1) and rs11037575 
(HSD17B12) when we performed a Matched Co-Twin Analysis, which 
permits immediate replication and validation of expression quantitative 
trait loci discoveries. 
   The qRT-PCR gene expression analysis showed that mRNA 
expression of full length BARD1 isoform was significantly higher in NBL 
cell lines heterozygous at rs7585356 (AG) (Figure 9a). A trend toward 
association between high mRNA levels of full length HSD17B12 isoform 
and presence of the risk allele C was observed for rs11037575 without 
reaching the threshold for statistical significance (Figure 9b). 
 
 
 
    
Figure 9. Gene expression analysis of BARD1 and HSD17B12 in NBL cell lines. 
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To select those SNPs independently associated with NBL among the 13 
replicated ones, we performed a LD analysis using data from 1000 
Genomes Project (http://www.broadinstitute.org/mpg/snap/index.php). SNPs 
with a r2 >0.10 with the most significant SNP within each gene were 
removed: eight SNPs (rs6939340 (LINC00340), rs6435862 and 
rs7585356 (BARD1), rs110419 (LMO1), rs1027702 (DUSP12), 
rs11037575 (HSD17B12), rs4336470 (HACE1) and rs17065417 
(LIN28B) were selected for further analyses. Interestingly, the LD and 
haplotype analyses demonstrated that SNPs rs6435862 and rs7585356 
of BARD1 were located in two independent genetic loci.  
  To demonstrate the independence of their association with NBL risk, 
we conducted a logistic regression analysis by adjusting for either of the 
two SNPs. The results showed that both SNPs still remained significant 
in  Italians (rs6435862: p=1.7x10-4, OR=1.97, 95% CI: 1.60-2.43; 
rs7585356: p=0.04, OR=0.80, 95% CI: 0.64-0.99). 
   The association of these eight independent risk variants and NBL 
stratified by clinical stage (stage 4 versus not stage 4), MYCN status 
(amplified versus not amplified), risk assessment (high-risk versus not 
high-risk), and age at diagnosis (age ≥18 months and <18 months) was 
further evaluated among cases. As shown in table 4, the genetic variants 
of LINC00340 (Maris et al. 2008), BARD1 (Capasso et al. 2009) and 
LMO1 (Wang et al. 2011) confirmed the association with more clinically 
aggressive phenotypes, but only rs7585356 resulted to be significantly 
associated with stage 4 and age≥18 months (P=0.04, OR= 0.67, 95% 
CI=0.46-0.98 and P=0.02, OR=0.64, 95% CI=0.44-0.92). 
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   Moreover, it was evaluated potential pairwise interaction effects 
among the studied SNPs. No evidence of epistasis was detected through 
this analysis.  
   To further investigated the cumulative effects of the eight 
susceptibility loci on NBL development in Italians the total number of 
risk alleles carried by individual subjects was used as predictor.  
  The distribution of risk alleles carried in both cases and controls 
followed a normal distribution, but with a shift toward a higher number 
of risk alleles in the cases (Figure 10a).   
Table 4. Association of the eight genetic variants with pathologic characteristic of NBL. 
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   As shown in figure 11a, individuals with multiple risk alleles had 
higher risk of developing NBL compared to those with 0-7 risk alleles of 
the eight variants, in a dose-dependent manner with increasing number 
of risk variant alleles (p-trend=8.55x10-13, OR=1.35, 95% CI:1.24-
1.46). We also tested for the cumulative effects of the four genetic 
variants (rs6939340, rs6435862, rs7585356, rs110419) significantly 
found to be associated with clinically aggressive NBL in European 
Americans (Capasso et al. 2013). The distribution of risk alleles carried 
in both not high-risk and high-risk patients is shown in figure 10b. A 
shift toward a higher number of risk alleles in high-risk individuals was 
observed but it was not so evident  in Italians. As shown in figure 11b, 
the ORs relative to the 0-3 risk alleles group increased with increasing 
number of risk alleles in Italians without reaching the threshold for 
statistical significance (p-trend=2.2x10-1, OR=1.11, 95% CI: 0.94-1.30),  
 
Figure 10. Distribution of risk alleles in healthy controls and NBL cases for the identified NBL 
(a) and aggressive disease phenotype (b) susceptibility loci. 
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Replication study on IL-6 promoter polymorphism. 
   The allele frequencies for rs1800795 for NBL patients and controls 
are shown in table 5. The distribution of the genotypes was in 
agreement with HWE. The genotype CC was more significantly frequent 
in high-risk (p=0.03) and stage 3 and 4 patients (p=0.02). No significant 
association was found with NBL development. 
 
 
 
Genotypic frequencies 
    
 
GG    
(%) 
GC    
(%) 
CC    
(%) 
aP aOR (CI=95%) bP 
bOR 
(CI=95%) 
Cases 
176 
(0.54) 
125 
(0.38) 
25 
(0.08) 
0.24 
1.14 
(0.92-1.43) 
0.34 
1.31 
(0.75- 2.28) 
Controls 
295 
(0.58) 
184 
(0.36) 
32 
(0.06)     
Age 
       
> 18 months 
77 
(0.50) 
63 
(0.41) 
12 
(0.08) 
0.39 
1.17 
(0.82-1.65) 
0.65 
1.22 
(0.52-2.87) 
< 18 months 
94 
(0.56) 
62 
(0.37) 
12 
(0.07)     
Sex 
       
Male 
92 
(0.52) 
72 
(0.40) 
14 
(0.08) 
0.41 
1.16 
(0.81-1.65) 
0.52 
1.34 
(0.55–2.35) 
Figure 11. Plots showing the increasing ORs for a) NBL patients and b) high-risk patients with 
the increasing number of risk alleles for the identified loci. The vertical bars represent 95% 
CIs. The horizontal line denotes the null value (OR=1). 
Table 5. Allele frequencies for rs1800795 for NBL patients and controls. 
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Female 
79 
(0.56) 
53 
(0.38) 
9 (0.06) 
    
INSS stage 
       
Stage 1 + 2 
57 
(0.55) 
44 
(0.43) 
2 (0.02) c0.21 
1.29 
(0.87-1.91) 
c0.02 
5.03 
(1.13-22.46) 
Stage 3 + 4 
102 
(0.53) 
72 
(0.37) 
18 
(0.09)     
Stage 4S 
12 
(0.52) 
8 (0.35) 3 (0.13) 
    
Risk 
       
High-risk 
73 
(0.51) 
55 
(0.38) 
16 
(0.11) 
0.08 
1.36 
(0.96-1.92) 
0.03 
2.51 
(1.05-5.99) 
Not high-risk 
103 
(0.57) 
70 
(0.38) 
9 (0.05) 
    
MYCN 
       
Amplified 
35 
(0.48) 
32 
(0.44) 
6 (0.08) 0.17 
1.33 
(0.88- 2.02) 
0.33 
1.66 
(0.59-4.69) 
Not Amplified 
126 
(0.57) 
82 
(0.37) 
13 
(0.06)     
ap-values and ORs from comparison of allelic frequencies   
bp-values and ORs from comparison of genotype frequencies (GG/GC vs CC) 
cp-values and ORs from comparison of Stage 1 + Stage 2 patients vs Stage 3 + Stage 4 patients 
       
  
   Then we examined OS of the genotyped patients samples to 
determine if the IL-6 SNP was predictive of NBL outcome. IL-6 SNP 
showed statistically significant differences (p<0.05) in predicting OS. 
Indeed, patients that were homozygous for the C allele had worse 
survival than patients who were homozygous and heterozygous for the 
G allele in all patients (Figure 12A) and not MYCN amplified (Figure 
12B) patient sub-group. OS 5 years from the date of diagnosis was 
85.2% (95% CI 0.83-0.87) for the group of patients carrying GG and GC 
genotype, compared with 67.2% (95% CI 0.55-0.79) for the group of 
patients carrying CC genotype (Figure 12A). This genetic association 
was independent from MYCN status, age and INSS stage (table 6). A 
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similar trend, without reaching the significance, was observed when the 
analysis was restricted to high-risk patients (Figure 12C and 12D). 
 
 
 
 
 
 
 
 
 
 
 
 
A 
P=0.004 
B 
P=0.02 
P=0.48 
D 
P=0.27 
C 
All patients All patients 
High-risk patients High-risk patients 
GG/GC 
CC 
GG/GC 
CC 
CC CC 
GG/GC GG/GC 
Figure 12. Kaplan-Meier curves for OS rates. OS rates were compared between CC and 
any G (GC or CC) for the SNP IL-6 -174 in (A) all NB and (B) not MYCN amplified patients, 
and (C) in high-risk NB and (D) not MYCN amplified patients.frequencies for rs1800795 
for NBL patients and controls. 
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Table 6. Test for independent statistical significance of -174 IL-6 SNP after 
adjustment for NBL risk factors. 
  
Model HR (95% CI) P 
A. 
  
Age (≥18 months vs <18 months)  4.18 (2.55-6.84) <0.0001 
-174 IL6 SNP (CC vs GC/GG) 1.90 (1.05-3.43) 0.03 
B. 
  
MYCN (amplified vs not amplified) 3.85 (2.48-5.98) <0.0001 
-174 IL6 SNP (CC vs GC/GG) 1.95 (1.03-3.68) 0.04 
C. 
  
INSS Stage (4 vs 1-2-3-4s) 9.06 (5.11-16.08) <0.0001 
-174 IL6 SNP (CC vs GC/GG) 1.90 (1.05-3.42) 0.03 
 
   The in silico analysis of LCLs demonstrated that the CC genotype 
correlated with high level of IL-6 expression (p=2.61x10-5, Figure 13A). 
Subsequently, qRT-PCR of mRNAs from tumor specimens was 
performed and the results showed that the levels of IL-6 mRNA were 
higher in CC carriers than in GG and GC carriers (p=0.27, Figure 13B) 
without reaching the significant threshold. 
   When we verified the association of IL-6 gene expression with 
outcome disease in two independent sets of patients, we found that the 
increase of the mRNA expression was significantly associated with 
lower OS and progression of disease (Figure 13C, 13D and 13E). 
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P=0.007 
Low IL-6 (n=44) 
High IL-6 (n=44) 
P=0.013 
Low IL-6 (n=44) 
High IL-6 (n=44) 
P=0.003 
Low IL-6 (n=51) 
High IL-6 (n=51) 
All patients All patients Stage 4, No MYCN 
P=2.61x10-5 
IL
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N
A
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Figure 13. SNP-gene expression and IL-6 gene expression-outcome correlations. In silico 
and qRT-PCR analysis of IL-6 mRNA expression in (A) 198 LCLs and (B) 31 NBL tumors, 
respectively, stratified according to the SNP IL-6 -174. Kaplan-Meier analysis is shown, 
with individuals grouped by median of expression of IL-6 for OS and Progression Free 
Survival rates in (C and D) 88 NBL patients and (E) 102 INSS stage 4 patients with MYCN 
not amplified. 
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Discussion. 
   In this study, a  number of GWAS-identified NBL susceptibility loci in 
Italian NBL patients and healthy controls have been replicated. All SNPs at 
the BARD1 locus showed a strong association while the association with 
SNPs in LINC00340, LMO1, DUSP12, HSD17B12, HACE1, LIN28B was more 
moderate. SNPs at the DDX4 and IL31RA locus showed a trend towards 
association with NBL, but did not reach statistical significance. 
   Interestingly, SNP rs7585356 located 3’ downstream of BARD1 was 
found to be an additional and independent risk factor for NBL. These 
findings strengthen the role of BARD1 as NBL susceptibility gene. Indeed, 
it has already demonstrated that the genetic variant rs6435862 was 
strongly associated with high-risk NBL (Capasso et al. 2009) and 
correlated with high expression of the oncogenic BARD1β isoform (lacking 
exon 2 and 3), that led to an increased tumorigenicity of NBL cell lines 
(Bosse et al. 2012). Recently, NBL SNP association at the BARD1 locus has 
been replicated in African-Americans while limited association has been 
found at LINC00340 and LMO1 in the same population (Latorre et al. 
2012).  
   In this study it has been demonstrated that rs7585356, independently 
from rs6435862, was associated with NBL and also influenced full length 
BARD1 isoform expression in NBL cell lines. Based on these data, it is 
evident that more than one disease-contributing BARD1 variant may exist. 
   Moreover, the less frequent genotype of SNP rs7585356 showed a 
protective role in NBL development and a correlation with increased 
expression of the full length BARD1 isoform. This suggests an onco-
suppressor role of BARD1 in the biology of neuroblastic malignant 
transformation, as also recently indicated for colon tumorigenesis (Sporn 
et al. 2011).  
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   The genetic association analysis of clinical NBL phenotypes 
demonstrated that only BARD1 SNP rs7585356 showed a significant 
association with advanced INSS stage and age>18 months. This lack of 
association to the other SNPs is due to insufficient statistical power 
because of the limited sample size.  
   These findings indicate that NBL could arise from some as yet unknown 
combination of relatively common SNPs that can cumulatively increase the 
risk of a neuroblastic malignant transformation. No combinations of 
genotypes at the eight SNPs showed evidence of interaction. 
   One of the major goals of this work was to determine the cumulative 
effect of these variants on NBL risk demonstrating that although individual 
susceptibility alleles only moderately increase the risk of NBL, the risk 
becomes substantial when risk alleles are combined.  
   The other task of my study was the replication of the association study 
for a SNP within IL-6 polymorphism. It has been demonstrated that Italian 
NBL patients homozygous for the C allele had a worse outcome than 
patients homozygous or heterozygous for the G allele. No association was 
found when the analysis was restricted to high-risk patients. Moreover, it 
has been identified a genetic association between IL-6 CC genotype and 
high-risk phenotype and INSS stage 3 and 4. In contrast, a recent study by 
Lagmay et al. (2009) reported the genotype GG of the SNP  (-174 G>C) in  
promoter as responsible of a worse outcome in patients with high-risk 
NBL. Results from previous studies concerning the effect of IL-6 -174 on 
expression, cancer risk or survival are contradictory (Belluco C et al. 2003; 
Boiardi L et al. 2006; Bruunsgaard H et al. 2004; Jones KG et al. 2001; 
Fishman D et al. 1998; Landi S et al. 2003). In this genetic study, compared 
to that of Lagmay et al. (2009), a greater number of affected children have 
been analyzed, in addition to a pretty large sample of healthy individuals.  
   Subsequently, we evaluated the impact of the SNP on IL-6 gene 
expression in LCLs and NBL patients. The C allele has been described to 
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correlate with increased IL-6 serum levels (Jones KG et al. 2001; Fishman 
D et al. 1998). Other studies have associated the C allele with lower IL-6 
serum levels (Belluco C et al. 2003; Boiardi L et al. 2006; Bruunsgaard H et 
al. 2004; Jones KG et al. 2001; Fishman D et al. 1998). My results showed 
an alteration in IL-6 mRNA expression that results increased in subjects 
homozygous for the C allele. These findings are intriguing because a strong 
association between high levels of IL-6 and poor outcome in two gene 
expression array datasets composed of NBL patients was noted. However, 
given contradictory results, more investigations are needed to establish 
the effective genotype of the SNP in IL-6 promoter associated with clinical 
outcome of NB. 
   These data suggest a role for the SNP in influencing transcription and 
synthesis of IL-6 and support the idea that IL-6 could be a marker of NBL 
progression. Indeed, IL-6 seems to play a role in chemioresistance. Ara et 
al. (2009) has demonstrated the protective effect of IL-6 on drug-induced 
apoptosis in NBL. Retinoic acid, currently used for NBL therapy, seems to 
inhibit cell growth by down-modulation of the expression of IL-6 receptor 
and the secretion of IL-6 (Sidell N et al. 1991). Moreover, IL-6 pathway can 
be targeted by the monoclonal antibody Tocilizumab used as therapy for 
rheumatoid arthritis (Paul-Pletzer K 2006). This suggests the possibility 
that the targeting of IL-6 pathway could be a therapeutic strategy also for 
NBL. 
   Although these findings, a large proportion of the heritability of NBL 
remains undefined. Future studies will focus on discovering other 
common and rare disease susceptibility variants and epistatic effects at 
known risk alleles. Probably, when a greater number of risk variants will 
be identified a more robust genetic score could be built which may allow 
subgroups of patients at different risks of developing NBL to be better 
distinguished. 
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Conclusions. 
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Conclusions. 
   The replication of genetic association findings remains the golden 
standards for results validation. 
   This study confirms that the majority of risk loci identified in European 
American children also affect susceptibility to NBL in Italian children. 
Moreover, it demonstrates that BARD1 is the most significant genetic 
contributor to NBL risk, exhibiting two independent risk variants.  
   This work also shows that the identified NBL susceptibility loci 
individually have a moderate effect size but when are combined may 
increase risk of NBL substantially. 
   Another important result shows that eight independent NBL-associated 
common genetic variants (rs6939340, rs6435862, rs7585356, rs110419, 
rs1027702, rs11037575, rs4336470, rs17065417) have been discovered 
and validated. Moreover, common variation within BARD1 may also 
influence BARD1 mRNA expression and maybe it influences BARD1 
splicing. 
   This study also supports the role of IL-6 in NBL as marker of disease 
progression, but additional studies are needed to clarify the role of the 
SNP rs1800795 (-174 G>C) in predicting the clinical outcome of patients 
with NBL and to define its function in affecting transcription and synthesis 
of IL-6. Indeed the biological effect of this SNP in relation to promotion of 
cancer progression is consistent with the observed decreased survival 
time. These findings suggest that the SNP IL-6 -174 may be useful marker 
for NBL prognosis. Given the contradictory results between this and the 
previous study on SNP IL-6 -174 more independent confirmatory 
evaluations are needed. 
   However these findings are just a “small piece” of the whole “puzzle” and 
further studies are needed. So, my next steps will be the characterization 
of the role of the SNPs within BARD1. Moreover, I planned to sequence the 
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whole BARD1 gene in one hundred both somatic and germ line DNA by 
high-throughput sequencing to define if acquired mutations are associated 
to NBL.  
   Another task may be the study of the gene-gene interactions between the 
predicted interactors of BARD1 (CDK2, BRCA2, PTN, UBE2D3, RBBP8) and 
BARD1 to understand their role in NBL progression and development. 
   All these tasks should lead us to better understand the events 
responsible of NBL progression and development. 
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Replication of GWAS-identi!ed neuroblastoma risk loci strengthens the role of BARD1 
and af!rms the cumulative effect of genetic variations on disease susceptibility
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Several neuroblastoma (NB) susceptibility loci have been identi-
!ed within LINC00340, BARD1, LMO1, DUSP12, HSD17B12, 
DDX4, IL31RA, HACE1 and LIN28B by genome-wide associa-
tion (GWA) studies including European American individuals. To 
validate and comprehensively evaluate the impact of the identi-
!ed NB variants on disease risk and phenotype, we analyzed 16 
single nucleotide polymorphisms (SNPs) in an Italian popula-
tion (370 cases and 809 controls). We assessed their regulatory 
activity on gene expression in lymphoblastoid (LCLs) and NB 
cell lines. We evaluated the cumulative effect of the independ-
ent loci on NB risk and high-risk phenotype development in 
Italian and European American (1627 cases and 2575 controls) 
populations. All NB susceptibility genes replicated in the Italian 
dataset except for DDX4 and IL31RA, and the most signi!cant 
SNP was rs6435862 in BARD1 (P = 8.4 × 10–15). BARD1 showed 
an additional and independent SNP association (rs7585356). This 
variant in$uenced BARD1 mRNA expression in LCLs and NB 
cell lines. No evidence of epistasis among the NB-associated vari-
ants was detected, whereas a cumulative effect of risk variants 
on NB risk (European Americans: Ptrend  =  6.9 × 10–30, Italians: 
Ptrend  =  8.55 × 1013) and development of high-risk phenotype 
(European Americans: Ptrend = 6.9 × 10–13, Italians: Ptrend = 2.2 × 10–1) 
was observed in a dose-dependent manner. These results provide 
further evidence that the risk loci identi!ed in GWA studies con-
tribute to NB susceptibility in distinct populations and strengthen 
the role of BARD1 as major genetic contributor to NB risk. This 
study shows that even in the absence of interaction the combina-
tion of several low-penetrance alleles has potential to distinguish 
subgroups of patients at different risks of developing NB.
Introduction
Neuroblastoma (NB) is a neuroendocrine tumor, arising from any 
neural crest element of the sympathetic nervous system. Despite its 
relative low incidence accounting for <1000 cases in the USA and 
150 cases in Italy per year, NB accounts for 15% of childhood cancer 
mortality (1). Currently, clinical trials stratify patients into four prog-
nostic subgroups with expected very low risk, low risk, intermediate 
risk, and high risk of death from disease, and 16 pretreatment desig-
nations (2). Stratifying patients according to risk subgroups represent 
an important strategy to choose an appropriate and effective therapy. 
However, children with severe clinical course and widespread metas-
tases categorized as ‘high risk’ have survival rates <35% despite 
aggressive and intensive therapies (1).
Recent genome-wide association studies (GWAS) demonstrated 
that common single nucleotide polymorphism (SNP) alleles were 
associated with NB. Some of these SNP associations were particu-
larly enriched in the high-risk group for long intergenic non-pro-
tein coding RNA 340 (LINC00340) (3), BRCA1-associated RING 
domain 1 (BARD1) (4), and LIM domain only 1 (LMO1) (5), and 
in the low-risk group for dual speci"city phosphatase 12 (DUSP12), 
hydroxysteroid (17-beta) dehydrogenase 12 (HSD17B12), DEAD 
(Asp-Glu-Ala-Asp) box polypeptide 4 (DDX4) and interleukin 31 
receptor A (IL31RA) (6). Additional SNPs within HECT domain and 
ankyrin repeat containing E3 ubiquitin protein ligase 1 (HACE1) and 
lin-28 homolog B (C. elegans) (LIN28B) have been found to be asso-
ciated with NB but not with disease phenotype (7). These "ndings 
suggested that in NB common variants affect both tumor initiation 
and malignant progression.
All of the NB GWAS have been performed in European American 
population samples. Some associated SNPs at LINC00340 (1), BARD1 
(4), and LMO1 (5) have been replicated in a North European sample 
from the UK and in an African American sample (8). It is well known 
that European Americans form a structured population due to historical 
immigration from diverse source populations, and this can create false-
positive genetic associations (9). Furthermore, among Europeans there 
is a consistent and reproducible distinction in SNP frequencies between 
‘‘northern’’ and ‘‘southern’’ population groups (10). Based on these 
observations, it is evident that con"rmatory studies are needed through 
replication in diverse populations to validate the GWAS "ndings.
In this study, we assessed the association of NB with eight SNPs 
(rs6939340 and rs4712653 located in LINC00340, and rs6435862, 
rs3768716, rs7585356, rs2070094, rs2229571 and rs1048108 located 
in BARD1) in a southern European population sample composed of 
370 cases and 809 controls of Italian origin. In addition, we extended 
to this larger group the study of rs110419 and rs4758051 (LMO1), 
rs1027702 (DUSP12), rs11037575 (HSD17B12), rs2619046 (DDX4) 
and rs10055201 (IL31RA) already genotyped in a smaller sample 
(5,6). The results of the Italian case-control study were compared with 
those of the European American GWAS composed of 1627 cases and 
2575 controls (6).
In our previous studies, we demonstrated that rs110419 in LMO1 
(5), rs6435862 in BARD1 (11), and rs17065417 in LIN28B (7) are 
functional regulatory variants and are involved in NB tumorigenicity. 
In this study, we tested for SNP–gene expression associations in 
lymphoblastoid (LCL) and NB cell lines. Finally, we evaluated the 
cumulative effect of each GWAS identi"ed and replicated genetic 
variants on NB risk and development of high-risk phenotype, and 
their potential interactions (epistasis), in both European American and 
Italian populations.
Materials and methods
Study subjects
This study consisted of 370 NB patients and 809 cancer-free controls of Italian 
origin. Case subjects were de"ned as children with a diagnosis of NB or gan-
glioneuroblastoma and collected through the Italian Neuroblastoma Group. 
The eligibility criterion for genotyping was the availability of DNA. All 
Abbreviations: CI, con"dence interval; GWA, genome-wide association; 
LCLs, lymphoblastoid cell lines; LD, linkage disequilibrium; NB, neuroblas-
toma; OR, odds ratio; SNPs, single nucleotide polymorphisms.
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control subjects were recruited from Italian blood donor centers. Eligibility 
criteria for control subjects were Italian origin, availability of DNA, no serious 
underlying medical disorder, including cancer.
In addition, this study included a GWAS dataset of 1627 NB patients regis-
tered through the North American-based Children’s Oncology Group (COG) and 
2575 cancer-free children of self-reported Caucasian ancestry who were recruited 
and genotyped by the Center for Applied Genomics at the Children’s Hospital 
of Philadelphia (CHOP). European American cases and controls have been 
described in detail in a previous publication (6). Case subjects were de"ned as 
children with a diagnosis of NB or ganglioneuroblastoma and registered through 
the Children’s Oncology Group. The blood samples from the patients with NB 
were identi"ed through the NB biorepository of the Children’s Oncology Group 
for specimen collection at the time of diagnosis. The eligibility criterion for 
genome-wide genotyping was the availability of 1.5 μg of DNA of high quality 
from a tumor-free source such as peripheral blood or bone marrow mononuclear 
cells that were uninvolved with a tumor. Control subjects were recruited from 
the Philadelphia region through the Children’s Hospital of Philadelphia Health 
Care Network, including four primary care clinics and several group practices and 
outpatient practices that included well-child visits. Eligibility criteria for control 
subjects were European ancestry as determined by self-report or parental report, 
availability of 1.5 μg of high-quality DNA from peripheral-blood mononuclear 
cells, and no serious underlying medical disorder, including cancer.
Main clinical and biological characteristics of the patients, including age, 
stage of the disease (International Neuroblastoma Staging System), and v-myc 
myelocytomatosis viral related oncogene, neuroblastoma derived ampli"cation 
status, are shown in Table I. Samples were assigned into two risk groups (not 
high risk and high risk) based on the Children’s Oncology Group risk assignment 
(1). This study was approved by the Ethics Committee of the Medical University 
of Naples. The participants of this study gave written informed consent.
SNP selection and genotyping
We selected for genotyping 14 genetic variants that have previously been asso-
ciated with NB in European American children. We included the two most 
signi"cant SNPs identi"ed in LINC00340 (intronic rs6939340 and rs4712653) 
(1), in BARD1 (intronic rs6435862 and rs3768716) (4) and in LMO1 (intronic 
rs110419 and intergenic rs4758051) (5) as previously reported. In addition, we 
genotyped the putative functional variation rs7585356 located 3′ downstream 
of BARD1, and its coding variants rs2070094, rs2229571 and rs1048108 (4). 
We also analyzed four SNPs (intergenic rs1027702 near DUSP12, intronic 
rs11037575 in HSD17B12, rs2619046 in DDX4 and rs10055201 in IL31RA) 
recently found to be associated with low-risk NB (6). The Italian DNA sam-
ples were genotyped using SNP Genotyping Assay on 7900HT Real-time PCR 
system (Applied Biosystems). To monitor quality control, three DNA samples 
per genotype were genotyped by Sanger sequencing (3730 DNA analyzer, 
Applied Biosystems) and included in each 384-well reaction plate; genotype 
concordance was 100%. To con"rm genotypes, we sequenced 20 samples 
chosen randomly from cases and controls; concordance between genotypes 
was 100%. Primer sequences are available on request. To test NB risk vari-
ants cumulative effect, we also used genotype data of rs4336470 (HACE1) and 
rs17065417 (LIN28B) already demonstrated to be associated with NB in this 
Italian case-control sample (7). The European American DNA samples were 
genotyped using the Illumina In"nium II BeadChip, HumanHap550 v1 and v3 
array (Illumina) according to methods detailed elsewhere (3,4). The quality 
control analyses for this GWAS dataset are described in detail elsewhere (6).
SNP–gene expression correlation analysis
The in#uence of SNPs on gene expression was evaluated using two web tools, 
SNPexp v1.2 (http://app3.titan.uio.no/biotools/tool.php?app=snpexp) (12) and 
Genevar v3.1.0 (http://www.sanger.ac.uk/resources/software/genevar/) (13). 
SNPexp calculates correlation between HapMap genotypes and gene expression 
levels in LCLs using linear regression under an additive model. For this analysis, 
198 unrelated HapMap3 subjects were chosen. In Genevar, a linear regression 
(under an additive model) was used to calculate the SNP–gene expression cor-
relations performing a matched co-twin analysis. The expression and genotype 
data were obtained from LCLs of 170 individuals separate in two sets, Twin 1 (81 
subjects) and Twin 2 (89 subjects). This analysis permits immediate replication 
and validation of the identi"ed SNP–gene expression associations.
Genotyping of NB cell lines
For routine maintenance, cells were grown in RPMI 1640 (Sigma–Aldrich, R8758) 
complete media or Dulbecco’s modi"ed Eagle’s medium (Sigma–Aldrich, D6546) 
complete media containing 10% fetal bovine serum (Sigma–Aldrich, F7524), 
1X Penicillin–Streptomycin (Sigma–Aldrich, P0781) and 2 mM l-Glutamine 
(Sigma–Aldrich, G7513). NB cell lines were genotyped for the HSD17B12-
SNP rs11037575 and for the BARD1-SNP rs7585356. Genomic DNA was iso-
lated using the Wizard Genomic DNA Puri"cation Kit (Promega Corporation, 
Madison, WI). DNA (50 ng) from NB cell lines was used as a template, and PCR 
amplicons were generated using Promega PCR Master Mix. The DNA primer 
sequences were ‘rs11037575’ forward: 5′-GGTGGGTGTGCATTCTTTT-3′; 
reverse: 5′-TACTTGCCTTTGGCCCATTA-3′; and ‘rs7585356’ forward: 
5′-GTTCATGAGGAACCAAACTGG-3′; reverse: 5′-TGGAGGCAGAAGTTG 
GTGAT-3′. Each amplicon was isolated on 1% agarose gel and puri"ed using 
QIAamp puri"cation kit (Qiagen). Finally, each amplicon was sequenced using 
3730 DNA analyzer (Applied Biosystems). The NB cell lines and genotypes are 
reported in the Supplementary Table 1, available at Carcinogenesis Online.
Gene expression of NB cell lines
RNA was isolated from NB cell lines using the TRIzol reagent (Invitrogen Life 
Technologies). Two hundred nanograms of total RNA was reverse transcribed into 
cDNA using iScript cDNA Synthesis Kit (Bio-Rad). Quantitative RT–PCR (qRT–
PCR) using Power SYBR Green PCR Master Mix (Applied Biosystems) was 
performed to evaluate the gene expression of HSD17B12 and BARD1. Samples 
were ampli"ed on an Applied Biosystems 7900HT Sequence Detection System 
using standard cycling conditions and data collected and analyzed by 2^–∆ct method 
as described in our previous article (14). β-Actin gene was used as housekeeping 
gene. Primers overlapping the exon–exon junction were used. Primer sequences 
were as follows: ‘HSD17B12’ forward: 5′-TTGTAGATTTCTTCTCTCAGTG-3′; 
reverse: 5′-GCAGGACACTCTGCACAAA-3′; ‘BARD1’ forward: 5′-GAC 
AACTGGACAGCATGATTCAA-3′; reverse: 5′-TTGTTTCCTGCATCATTA 
AACAAAC-3′. Primers used for HSD17B12 and BARD1 were speci"cally 
designed to detect the cDNA full lenght isoforms.
Genotype imputation on chromosome 2q35 data
As SNPs rs7585356, rs2070094, rs2229571 and rs1048108 of BARD1 were not 
included in Illumina HumanHap550 arrays, genotype imputation was performed 
in the European American GWAS dataset using PLINK software v1.06 (15). The 
HapMap genotypes (release 23) of CEU subjects, downloaded from the HapMap 
database (http://www.hapmap.org), were used as reference. A total of 1071 SNPs of 
the 2q35 band included in the arrays were used to perform the imputation analysis.
Statistical analysis
Hardy–Weinberg equilibrium was evaluated using the goodness-of-"t chi-
square test in control subjects. Two-sided chi-square tests were used to 
Table I. Clinical characteristic of study sample
Italians European Americans
Cases
n = 370 n = 1627 Pa
Variable Number (%) Number (%)
Age
 >=18 months 170 (46.8)  744 (52.9) 0.04
 <18 months 193 (53.2)  662 (47.1)
 Unknown  7  221
Sex
 Male 203 (56.1)  865 (53.2) 0.31
 Female 159 (43.9)  762 (46.8)
 Unknown  8  —
INSS Stage
 4 145 (40.2)  605 (43.2) 0.30
 1,2,3,4s 216 (59.8)  795 (56.8)
 Unknown  9  227
MYCN
 Ampli"ed  80 (24.0)  233 (17.3) 0.005
 Not ampli"ed 254 (76.0) 1111 (82.7)
 Unknown  36  283
Risk
 High risk 212 (57.3)  595 (43.7) 0.000003
 Not high risk 158 (42.7)  767 (56.3)
 Unknown —  265
Controls
n = 809 n = 2572
Variable Number (%) Number (%)
Sex
 Male 458 (56.6) 1325 (51.5) 0.01
 Female 351 (42.3) 1247 (48.4)
Age (mean years; SD)b 10.1 (6.4)   9.4 (5.6) 0.002
aStatistical comparison of clinical variables between the two case and control groups.
bAge data were not available for 359 European Americans 
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evaluate differences in the distributions of allele frequencies 
between all patients and controls, and only high-risk patients and 
controls. Odds ratios (ORs) and 95% con"dence intervals (CIs) 
were calculated to assess the relative disease risk conferred by a 
speci"c allele. We de"ned replication as a P ≤ 0.05 with a consist-
ent direction of association. We did not correct for multiple tests 
because the analyzed genes were previously reported associated to 
NB in multiple independent datasets (3–6,8). Student’s t-test was 
used to compare the differences in the mRNA expression levels 
between NB cell lines strati"ed according to genotype. Linkage 
disequilibrium (LD) and haplotype analysis were performed using 
the web-site tool SNAP v2.2 (http://www.broadinstitute.org/
mpg/snap/index.php) (16) and Haploview v4.2 software (17). We 
assessed the cumulative effects of the independent signi"cant risk 
loci on NB initiation and phenotype, by counting the number of 
risk alleles in each subject and modeling the summary variable cat-
egorically in logistic regression analysis. The alleles with higher 
frequency in cases than controls for each SNP were de"ned as 
‘risk alleles’, and genotypes were coded as 0, 1 or 2 according to 
the number of risk alleles. Cumulative risk scores were calculated 
for all SNPs and patients were grouped into categories based on 
the number of risk alleles 0–7, 8, 9, 10, 11–15 for case-control 
comparison, and 0–3, 4–5, 6–8 for case-only (high-risk versus not 
high-risk phenotype comparison). The risk categories were created 
keeping similar percentage of individuals in each group. For the 
case-only comparison of high-risk against not high-risk phenotype, 
we created only three risk categories to have more statistical power 
as the number of SNPs and patients was lower than in the case-
control group. ORs were calculated comparing the groups de"ned 
by varying number of risk alleles to the group with the lowest num-
ber of risk alleles (0–7 for the case-control analysis and 0–3 for the 
case-only analysis). A P value of ≤0.05 was considered as statisti-
cally signi"cant. This analysis was performed using IBM SPSS 
19.0 software. Gene–gene interaction was tested using logistic 
regression additive model by adding an interaction term between 
the genotypes from all pair of SNPs investigated. This analysis was 
performed by PLINK software v1.06 (15).
Results
Table I shows the clinical parameters of 370 and 1627 NB 
patients with Italian and European American origin, respectively. 
The allele frequencies of all selected genetic variants among 
cases and controls and their association with NB and high-risk 
phenotype are shown in Table II and Supplementary Table 2, 
available at Carcinogenesis Online. Because SNPs rs7585356, 
rs2070094, rs2229571 and rs1048108 were not included in the 
European American study, we performed genotype imputation 
at 2q35 (Supplementary Table 3, available at Carcinogenesis 
Online). The most signi"cant imputed SNP was rs17487827, 
which is in strong LD with genotyped markers rs3768716 and 
rs6435862 (r2 = 0.95 and 0.60, respectively in 1000 Genomes 
Project data). The observed genotype frequencies among the 
control subjects were in agreement with Hardy–Weinberg equi-
librium, except for rs2070094 (P < 0.001) in Italian children. 
This SNP was excluded from further analyses. Table III sum-
marizes the characteristics of the studied SNPs.
In the Italian case-control study, signi"cant differences 
of allele distributions were observed for all SNPs except 
rs4758051 (LMO1), rs2619046 (DDX4) and rs10055201 
(IL31RA). SNP rs6435862 within BARD1 was the most 
signi"cant (Table II, P = 8.4 × 10–15). All SNPs showed a 
similar pattern of association to NB in Italian and European 
American children. All SNPs of LINC00340 and BARD1, 
and one of LMO1 were signi"cantly associated with high-
risk NB in both populations (Table II and Supplementary 
Table 2, available at Carcinogenesis Online).
We then tested for SNP–gene expression associations at 
all 14 SNPs and at 2 previously reported SNPs (7). The 
analysis of gene expression variation using genome-wide 
expression arrays from LCLs of 198 unrelated HapMap 
individuals demonstrated that SNPs rs7585356 (BARD1), Ta
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rs1027702 (DUSP12), rs4336470 (HACE1) and rs11037575 
(HSD17B12) affected expression of the respective genes (Table 
II). These results were con"rmed in 170 additional LCLs only for 
rs7585356 (BARD1) and rs11037575 (HSD17B12) when we performed 
a matched co-twin analysis, which permits immediate replication and 
validation of expression quantitative trait loci discoveries (Table II, 
Supplementary Figure 1, available at Carcinogenesis Online). These 
analyses demonstrated a high reproducibility of results for these two 
putative regulatory variants, whereas the other SNPs did not show 
the same results in different populations. Therefore, a qRT–PCR 
gene expression analysis was performed only for rs7585356 and 
rs11037575. The mRNA expression of full length BARD1 isoform 
was signi"cantly higher in NB cell lines heterozygous at rs7585356 
(AG) (Figure 1a). A  trend toward association between high mRNA 
levels of full length HSD17B12 isoform and presence of the risk allele 
C was observed for rs11037575 without reaching the threshold for 
statistical signi"cance (Figure 1b).
To select SNPs independently associated with NB among the 
13 replicated ones, we performed a LD analysis using data from 
1000 Genomes Project (http://www.broadinstitute.org/mpg/snap/
index.php). SNPs with a r2 > 0.10 with the most signi"cant SNP 
within each gene were removed (Supplementary Table 4, available 
at Carcinogenesis Online). Consequently, eight SNPs (rs6939340 
(LINC00340), rs6435862 and rs7585356 (BARD1), rs110419 
(LMO1), rs1027702 (DUSP12), rs11037575 (HSD17B12), rs4336470 
(HACE1) and rs17065417 (LIN28B) were selected for further analy-
ses. Of note, the LD and haplotype analyses demonstrated that SNPs 
rs6435862 and rs7585356 of BARD1 were located in two independ-
ent genetic loci (Supplementary Figure 2, available at Carcinogenesis 
Online). To con"rm the independence of their association with NB 
risk, we conducted a logistic regression analysis by adjusting for either 
of the two SNPs, and found that both SNPs still remained signi"cant 
in European Americans (rs6435862: P = 1.8 × 10–10, OR = 1.25, 95% 
CI: 1.11–1.40; rs7585356: P = 0.04, OR = 0.88, 95% CI: 0.78–0.99) 
and Italians (rs6435862: P = 1.7 × 10–4, OR = 1.97, 95% CI: 1.60–
2.43; rs7585356: P = 0.04, OR = 0.80, 95% CI: 0.64–0.99).
The association of these eight independent risk variants and NB 
strati"ed by clinical stage (stage 4 versus not stage 4), MYCN status 
(ampli"ed versus not ampli"ed), risk assessment (high risk versus not 
high risk), and age at diagnosis (age ≥18 months and <18 months) 
was further evaluated among Italian and European American cases. 
As shown in Table IV, in the European American sample the genetic 
variants of LINC00340 (3), BARD1 (4) and LMO1 (5) con"rmed the 
association with more clinically aggressive phenotypes, as already 
demonstrated in the previous articles. In the Italian patients, these 
SNPs showed the same trend for association, but only rs7585356 
Fig. 1. qRT–PCR analysis to test the SNP–gene expression correlation in neuroblastoma (NB) cell lines. (a) mRNA expression of full length BARD1 isoform in 
NB cell lines strati"ed according to rs7585356 genotype. No NB cell lines carried the genotype AA. (b) mRNA expression of full length HSD17B12 isoform in 
NB cell lines strati"ed according to rs11037575 genotype.
Table III. Features of analyzed SNPs
n SNP ID Chromosome band Function Allelea Italian dataset SNP type EA dataset SNP type
1 LINC00340 (rs6939340) 6p22 — A/G Genotyped Genotyped
2 LINC00340 (rs4712653) 6p22 — T/C Genotyped Genotyped
3 BARD1 (rs6435862) 2q35 Intronic T/G Genotyped Genotyped
4 BARD1 (rs3768716) 2q35 Intronic A/G Genotyped Genotyped
5 BARD1 (rs7585356) 2q35 3′downstream G/A Genotyped Imupted
6 BARD1b (rs2070094) 2q35 Exon 6 (Val507Met) G/A Genotyped —
7 BARD1 (rs2229571) 2q35 Exon 4 (Arg378Ser) G/C Genotyped Imupted
8 BARD1 (rs1048108) 2q35 Exon 1 (Pro24Ser) C/T Genotyped Imupted
9 LMO1 (rs110419) 11p15 Intronic G/A Genotyped Genotyped
10 LMO1 (rs4758051) 11p15 Intergenic A/G Genotyped Genotyped
11 DUSP12 (rs1027702) 1q23.3 Intergenic C/T Genotyped Genotyped
12 HSD17B12 (rs11037575) 11p11.2 Intronic T/C Genotyped Genotyped
13 DDX4 (rs2619046) 5p15.2-p13.1 Intronic G/A Genotyped Genotyped
14 IL31RA (rs10055201) 5p15.2-p13.1 Intronic A/G Genotyped Genotyped
15 HACE1 (rs4336470) 6q16.3 Intronic C/T Genotypedc Genotyped
16 LIN28B (rs17065417) 6q21 Intronic A/C Genotypedc Genotyped
aMajor/minor alleles. bExcluded as not in agreement with Hardy–Weinberg equilibrium.
cAlready genotyped in Diskin et al. 2012.
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resulted to be signi"cantly associated with stage 4 and age ≥18 months 
(P = 0.04, OR = 0.67, 95% CI = 0.46–0.98 and P = 0.02, OR = 0.64, 
95% CI = 0.44–0.92).
We evaluated potential pairwise interaction effects among the 
studied SNPs. No evidence of epistasis was detected through this 
analysis in both populations (Supplementary Table  5, available at 
Carcinogenesis Online). We further investigated the cumulative 
effects of the eight susceptibility loci on NB development in both 
populations using as predictor the total number of risk alleles car-
ried by individual subjects. In European Americans, the distribu-
tion of risk alleles carried in both cases and controls followed a 
normal distribution, but with a shift toward a higher number of risk 
alleles in the cases. This result was con"rmed in Italian population 
(Supplementary Figure 3a, available at Carcinogenesis Online). As 
shown in Figure  2a, European American individuals with multiple 
risk alleles had higher risk of developing NB compared with those 
with 0–7 risk alleles of the eight variants, in a dose-dependent manner 
with increasing number of risk alleles (Ptrend = 6.9 × 10
–30, OR = 1.23, 
95% CI: 1.19–1.28). We were able to con"rm this result in Italian 
(Ptrend = 8.55 × 10
–13, OR = 1.35, 95% CI: 1.24–1.46). We also tested 
for the cumulative effects of the four genetic variants (rs6939340, 
rs6435862, rs7585356 and rs110419) signi"cantly found to be associ-
ated with clinically aggressive NB subgroups in European Americans 
(Table IV). The distribution of risk alleles carried in both not high-risk 
and high-risk patients is shown in Supplementary Figure 3b, avail-
able at Carcinogenesis Online. A shift toward a higher number of risk 
alleles in high-risk individuals was observed in European Americans 
but it was less evident in Italians. As shown in Figure 2b, the OR rela-
tive to the 0–3 risk alleles group signi"cantly increased with increas-
ing number of risk alleles in European Americans (Ptrend = 6.9 × 10
–13, 
OR = 1.38, 95% CI: 1.26–1.51). The same trend was con"rmed in 
Italians without reaching the threshold for statistical signi"cance 
(Ptrend = 2.2 × 10
-1, OR = 1.11, 95% CI: 0.94–1.30).
Discussion
In this study, we set out to replicate a number of GWAS-identi"ed NB 
susceptibility loci in Italian NB patients and healthy controls. All SNPs 
at the BARD1 locus showed a strong association, whereas the association 
with SNPs in LINC00340, LMO1, DUSP12, HSD17B12, HACE1 and 
LIN28B was more moderate. SNPs at the DDX4 and IL31RA locus 
showed a trend toward association with NB, but did not reach statistical 
signi"cance. Interestingly, SNP rs7585356 located 3′ downstream of 
BARD1 was found to be an additional and independent risk factor for 
NB. These "ndings strengthen the role of BARD1 as NB susceptibility 
gene. Indeed, we have already demonstrated that the genetic variant 
rs6435862 was strongly associated with high-risk NB (4) and correlated 
with high expression of the oncogenic BARD1β isoform (lacking exons 
2 and 3), that led to an increased tumorigenicity of NB cell lines (11). 
Recently, NB SNP association at the BARD1 locus has been replicated 
in African Americans, whereas limited association has been found at 
LINC00340 and LMO1 in the same population (8). In this study, we 
have demonstrated that rs7585356, independently from rs6435862, 
was associated with NB and also in#uenced full length BARD1 iso-
form expression in NB cell lines. Based on these data, it is evident that 
more than one disease-contributing BARD1 variant may exist. Of note, 
the less frequent genotype of SNP rs7585356 showed a protective role 
in NB development and a correlation with increased expression of the 
full length BARD1 isoform. This suggests an oncosuppressor role of 
BARD1 in the biology of neuroblastic malignant transformation, as also 
recently indicated for colon tumorigenesis (18). Given the complex 
structure of BARD1 that displays diverse domains (RING, ANK and 
BRCT), this gene has been indicated to have multiple functions (19). 
These functions might be regulated by the expression of differentially 
spliced isoforms. So, it is reasonable to hypothesize that common and 
rare variants might affect the expression of distinct BARD1 isoforms 
that in turn might have tumor suppression and oncogenic functions in 
NB. Further studies are needed to address this hypothesis.
Our genetic association analysis of clinical NB phenotypes con-
"rmed that four SNPs at LINC00340 (rs6939340), BARD1 (rs6435862 
and rs7585356) and LMO1 (rs110419) conferred an increased risk for 
high-risk phenotype in European American patients. In Italian patients, 
only BARD1 SNP rs7585356 showed a signi"cant association with 
advanced INSS stage and age older than 18 months. We hypothesize 
that this lack of association to the other SNPs is due to insuf"cient 
statistical power because of the limited sample size. Indeed, the trend 
toward association with clinically aggressive phenotypes was the same 
for all four variants in European American and Italian patients.
Fig. 2. Odds ratio for (a) neuroblastoma patients and (b) high-risk patients according to increasing number of risk alleles in Italian and European American 
cases for the identi"ed risk loci (a) rs6939340, rs6435862, rs7585356, rs110419, rs1027702, rs11037575, rs4336470 and rs17065417; (b) rs6939340, rs6435862, 
rs7585356 and rs110419). The vertical bars represent 95% con"dence intervals. The horizontal line denotes the null value (OR = 1).
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Genetic risk variants and neuroblastoma
This article shows that eight independent NB-associated com-
mon genetic variants (rs6939340, rs6435862, rs7585356, rs110419, 
rs1027702, rs11037575, rs4336470, rs17065417) have been validated 
in an Italian population. These "ndings indicate that NB could arise 
from some as yet unknown combination of relatively common SNPs 
that can cumulatively increase the risk of a neuroblastic malignant 
transformation in fetal or early childhood development. No pairwise 
combinations of genotypes at the eight SNPs showed evidence of inter-
action, de"ned as deviation from additivity of allelic effects at separate 
loci. One of the major goals of this work was to determine the cumula-
tive effect of these variants on NB risk. Performing separate genetic 
analyses in two independent populations, we have demonstrated that 
although individual susceptibility alleles only moderately increase the 
risk of NB, the risk becomes substantial when risk alleles are combined. 
When we tested for their cumulative effect, we found that children car-
rying 10–15 risk alleles had a 3.2-fold for European Americans and 
5-fold for Italians increased risk of developing NB compared with those 
who carried 0–7 risk alleles, indicating the importance of the combined 
independent risk loci in neuroblast carcinogenesis. We observed simi-
lar results when the same analysis was performed on high-risk patients 
using the four genetic variants associated with clinically aggressive 
phenotypes (rs6939340, rs6435862, rs7585356 and rs110419). Indeed, 
European American children with NB carrying 6–8 risk alleles had 
3.3-fold increased risk of developing high-risk NB compared with 
those who carried 0–3 risk alleles. In Italian patients the same risk was 
increased 1.6-fold, but it did not reach statistical signi"cance.
One limitation of our study is the relative small number of Italian 
cases and controls. This probably affects some of the observed results. 
For instance, we speculate that the lack of association between some 
of SNPs and clinical conditions and the not statistically signi"cant 
result of the risk allele cumulative analysis of high-risk patients are 
probably due to the limited power of the sample. However, in both 
analyses the trend toward association was similar in both Italian and 
European American populations. Surely, additional con"rmatory 
studies are needed in larger populations with diverse origins to further 
validate the hypothesis that heritable DNA variation in#uences the 
clinical course of the disease.
Our study suggests that the heritable DNA variation that in#u-
ences the initiation of NB and the clinical course of the disease has 
the potential to predict disease and more interestingly to predict 
high-risk NB. However, a large proportion of the heritability of NB 
remains unde"ned. Future studies will focus on discovering other 
common and rare disease susceptibility variants and epistatic effects 
at known risk alleles. We hypothesize that when a greater number 
of risk variants will be identi"ed a more robust genetic score could 
be built, which may allow subgroups of patients at different risks of 
developing NB to be better distinguished. Several "ndings have dem-
onstrated that NB is a type of tumor genetically and phenotypically 
heterogeneous (20). We think that the discriminatory power of com-
bined risk alleles analysis will improve with time because the number 
of reproducibly associated variants is likely to increase rapidly with 
increasing number of cases and controls, as we have already demon-
strated in our recent articles (5,7). We have planned to increase promi-
nently the number of cases from three diverse populations (European 
Americans, Italians and British individuals) within the next 5 years 
through a multicentric collaborative project. A genetic risk score that 
includes more risk alleles could be relevant in improving the current 
risk models of NB adding more prediction power to the well-known 
clinical and genetic markers such as age, INSS stage, MYCN status. 
However, to assess the applicability of SNPs in the risk classi"cation 
of NB, large prospective cohort studies will be needed.
In summary, our study con"rms that the majority of risk loci identi-
"ed in European American children also affect susceptibility to NB 
in Italian children and demonstrates compelling evidence of BARD1 
as the most signi"cant genetic contributor to NB risk, exhibiting two 
independent risk variants. This work also shows that the identi"ed NB 
susceptibility loci individually have a moderate effect size but when 
combined may increase risk of NB substantially.
Supplementary material
Supplementary Tables 1–5 and Figures 1–3 can be found at 
http://carcin.oxfordjournals.org/
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Abstract 
Background: Common variants in DNA may predispose to neuroblastoma (NB) onset and 
progression. The genotype GG of single nucleotide polymorphism (SNP) rs1800795 (-174G>C) in 
interleukin(IL)-6 promoter has been associated with lower survival in high-risk NB.  
Methods: To validate and evaluate the impact of IL-6 SNP rs1800795 on disease risk and 
phenotype, we analyzed an Italian population of 326 NB patients and 511 controls. We performed 
in silico and qRT-PCR analyses to evaluate the influence of the SNP on gene expression in 198 
lymphoblastoid cell lines (LCLs) and in 31 NB tumors, respectively. Kaplan-Meier analysis was 
used to verify if IL-6 gene expression is associated with patient survival. 
Results: The SNP was not implicated in susceptibility to NB development. The results indicated 
instead the minor frequent genotype CC as significantly associated with a reduction of the overall 
survival, advanced stage, and high-risk phenotype. The in silico analyses (p=2.61x10
-5
) and the 
qRT-PCR (p=0.27) showed similar trend indicating the genotype CC as correlated with increased 
level of IL-6 expression. Kaplan-Meier analysis demonstrated that high levels of IL-6 were 
associated with poor outcome of disease in two independent gene expression array datasets.  
Conclusions: The biological effect of this SNP in relation to promotion of cancer progression is 
consistent with the observed decreased survival time.  
Impact: This study suggests that the SNP IL-6 -174 may be useful marker for NB prognosis. Given 
the contradictory results between this and the previous study on SNP IL-6 -174 more independent 
confirmatory evaluations are needed. 
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Introduction 
Neuroblastoma (NB) is a neuroendocrine tumor, arising from any neural crest element of the 
sympathetic nervous system. NB accounts for more than 7% of malignancies in children and around 
15% of pediatric oncologic deaths (1). In the last years we have demonstrated that common DNA 
variants located in diverse genes (LINC00340, BARD1, LMO1, DUSP12, HSD17B12, DDX4, 
IL31RA, HACE1 and LIN28B) predispose to NB onset and progression by genome-wide association 
studies (GWAS) (2-8). These findings suggested that NB tumorigenesis could be the result of 
different genetic alterations and some these alterations could also influence the clinical outcome of 
disease. 
Interleukin (IL)-6 is a pro-inflammatory cytokine that plays an active role in neoplasia, bone 
metabolism and iron homeostasis. Recent studies have demonstrated a role for IL-6 in progression 
and development of multiple myeloma, colon cancer, melanoma, renal cancer, Hodgkin’s disease, 
non-Hodgkin’s lymphoma, prostate cancer, breast cancer (9). The increase of IL-6 has been 
associated to the up-regulation of the expression of adhesion receptors on endothelial cells and to 
the production of growth factors. These events promoted the formation of favorable 
microenvironment for metastasis and suggested a role for IL-6 as a stimulator of metastasis (10-11). 
Moreover, it has been demonstrated that the peripheral blood levels of IL-6 correlated with NB 
progression and development (12) and that IL-6 promoted growth and survival of NB cells in the 
bone marrow (13). Interestingly, the studies by Lagmay et al. (14) reported the SNP rs1800795 (-
174 G>C) in IL-6 promoter as associated with inferior clinical outcomes in patients affected by 
high-risk NB. Replication of genetic association findings remains the golden standards for results 
validation. In this study, we evaluate whether the association of the germ-line polymorphism 
rs1800795 of IL-6 with NB survival is confirmed in an Italian population. We also verify if this 
SNP is associated with NB initiation. Finally, we tested for SNP-gene expression association in 
 5 
lymphoblastoid cell lines (LCLs) and in NB patients, and for the influence of IL-6 gene expression 
on patient survival. 
Materials and methods 
DNA samples. The study consisted of 326 DNAs extracted from peripheral blood of NB patients 
collected through the Italian Neuroblastoma Group and 511 DNAs from cancer-free controls of 
Italian origin (mean age 9.67 ± 5.41 year). Clinical and biologic characteristics of the patients are 
shown in Table 1. Samples were assigned into two risk groups (not high-risk and high-risk) based 
on the COG risk assignment (1). Tumor specimens were collected at the onset of disease from 31 
patients who were diagnosed with a primary NB between 1990 and 2006, and referred to the Gaslini 
Children Hospital, Genoa, Italy. The characteristics of tumors are reported in Supplementary Table 
S1. This study was approved by the Ethics Committee of the Medical University of Naples and 
informed consent was obtained by all children's legal guardians. 
rs1800795 (-174 G>C) genotyping. DNA samples were screened for the SNP rs1800795 using 
RFLP mapping to identify each patient’s genotype. The same RFLP mapping strategy described by 
Lagmay et al. (14) was used. Briefly, the method was PCR based and used primers that flank the 
SNP locus to produce an amplicon of 305 bp.  The PCR products were gel purified on 2% agarose 
and digested with the DNA restriction endonuclease Nla-III. The DNA primer sequences used were 
as follows: forward-ATGCCAAGTGCTGAGTCACTA; reverse-TCGAGGGCAGAATGAGCCTC. 
For quality control, 10% of randomly selected samples containing both cases and controls were 
analyzed at second time by Sanger sequencing (3730 DNA analyzer, Applied Biosystems) without 
finding any discrepancies. Genomic DNA from NB and control samples was isolated using the 
Wizard Genomic DNA Purification Kit (Promega Corporation, Madison, WI). 
In silico SNP-gene expression correlation analysis. The influence of the SNP on gene expression 
was evaluated using a web tool, SNPexp v1.2 
(http://app3.titan.uio.no/biotools/tool.php?app=snpexp) (15) as performed in our previous study (4). 
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SNPexp calculates correlation between HapMap genotypes and gene expression levels in LCLs 
using linear regression. For this analysis, 198 unrelated HapMap3 subjects were chosen.  
In silico analysis of IL-6 gene expression-outcome correlation. Two independent sets of 
normalized gene expression data and clinical annotations were downloaded from the website R2, 
microarray analysis and visualization platform (http://hgserver1.amc.nl/cgi-bin/r2/main.cgi): 
1) Versteeg dataset composed of 88 NB samples; 
2) Seeger dataset composed of 102 NB samples. 
IL-6 gene expression analysis in primary tumors. RNA from 31 NB tissues using the TRIzol 
reagent (Invitrogen Life Technologies). Two thousand ng of total RNA was reverse transcribed into 
cDNA using iScript cDNA Synthesis Kit (BIORAD). To evaluate the gene expression of IL-6, 
quantitative real time PCR (qRT-PCR) was performed using Power SYBR Green Master Mix 
(Applied Biosystems). Samples were amplified on an Applied Biosystems 7900HT Sequence 
Detection System using standard cycling conditions and data were collected and analyzed by 2^
-Δct
 
method as described in our previous paper (16). HPRT was used as housekeeping gene. Primers 
overlapping the exon-exon junction were used (IL-6 forward-TCTCCACAAGCGCCTTCGGT, IL-6 
reverse-TGGGGCAGGGAAGGCAGC; HPRT for: TGACACTGGCAAAACAATGCA, HPRT rev: 
GGTCCTTTTCACCAGCAAGCT). The primers for IL-6 were specific for the full length isoform.      
Statistical analysis. Hardy-Weinberg equilibrium was evaluated using the goodness-of-fit chi-
square test in control subjects. Two-sided chi-square tests were used to test for associations of the 
existence of polymorphism versus each other clinical factor, all patients, and only high-risk patients. 
Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to assess the disease risk 
conferred by a specific allele or genotype. Overall Survival (OS) was calculated by Kaplan-Meier 
method to generate survival curves which were compared using a log-rank test. The Cox regression 
model was used to test for the independent predictive ability of the SNP after the adjustment for 
other significant factors: MYCN amplification, age, INSS stages. P-values of <0.05 were considered 
statistically significant. 
 7 
Results 
IL-6 SNP genotyping. Allele frequencies for rs1800795 for NB patients and controls are shown in 
Table 1. The distribution of the genotypes was in agreement with Hardy–Weinberg equilibrium. 
The genotype CC was more significantly frequent in high-risk (p=0.03) and stage 3 and 4 patients 
(p=0.02). No significant association was found with NB development. 
Impact of the IL-6 SNP on OS. We examined OS of the genotyped patients samples to determine if 
the IL-6 SNP was predictive of NB outcome. IL-6 SNP showed statistically significant differences 
(p < 0.05) in predicting OS. Patients that were homozygous for the C allele had worse survival than 
patients who were homozygous and heterozygous for the G allele in all patients (Figure 1A) and not 
MYCN amplified (Figure 1B) patient sub-group. OS 5 years from the date of diagnosis was 85.2% 
(95% CI 0.83-0.87) for the group of patients carrying GG and GC genotype, compared with 67.2% 
(95% CI 0.55-0.79) for the group of patients carrying CC genotype (Figure 1A). This genetic 
association was independent from MYCN status, age and INSS stage (Supplementary Table S2). A 
similar trend, without reaching the significance, was observed when the analysis was restricted to 
high-risk patients (Figure 1C and 1D). 
SNP-gene expression analysis. The in silico analysis of LCLs demonstrated that the CC genotype 
correlated with high level of IL-6 expression (p=2.61x10
-5
, Figure 2A). qRT-PCR of  mRNAs from 
tumor specimens was performed. The levels of IL-6 mRNA were higher in CC carriers than in GG 
and GC carriers (p=0.27, Figure 2B) without reaching the significant threshold. 
IL-6 gene expression-outcome correlation. When we verified the association of IL-6 gene 
expression with outcome disease in two independent sets of patients, we found that the increase of 
the mRNA expression was significantly associated with lower OS and progression of disease 
(Figure 2C, 2D, and 2E). 
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Discussion 
Our recent findings have suggested that NB tumorigenesis could be the result of different genetic 
alterations that might also influence the clinical outcome of the disease (1-8). IL-6 is crucial 
cytokine involved in several cellular pathways (9). Peripheral blood and bone marrow IL-6 levels 
have been found to be elevated in patients with high-risk NB when compared with those with low 
and intermediate risk NB (12). We found that Italian NB patients homozygous for the C allele had a 
worse outcome than patients homozygous or heterozygous for the G allele. We found no association 
when the analysis was restricted to high-risk patients. We also identified a genetic association 
between IL-6 CC genotype and high-risk phenotype and INSS stage 3/4. In contrast, a recent study 
by Lagmay et al. (14) reported the genotype GG of the SNP  (-174 G>C) in  promoter as 
responsible of a worse outcome in patients with high-risk NB. Results from previous studies 
concerning the effect of IL-6 -174 on expression, cancer risk or survival are contradictory (17-22). 
In this genetic study compared to that of Lagmay et al. (14), we have analyzed a greater number of 
affected children, in addition to a pretty large sample of healthy individuals. The present study was 
particularly suitable for searching genetic association with NB as this Italian sample has been 
successfully used to validate GWAS-identified NB risk variants (4, 5, 7, 8). Moreover, we 
evaluated the impact of the SNP on IL-6 gene expression in LCLs and NB patients. The C allele has 
been described to correlate with increased IL-6 serum levels (20-21). Other studies have associated 
the C allele with lower IL-6 serum levels (17-21). Our results showed an alteration in IL-6 mRNA 
expression that results increased in subjects homozygous for the C allele. These findings are 
intriguing as we also found a strong association between high levels of IL-6 and poor outcome in 
two gene expression array datasets composed of NB patients. However, given contradictory results, 
more investigations are needed to establish the effective genotype of the SNP IL-6 -174 associated 
with clinical outcome of NB. 
These data suggest a role for the SNP in influencing transcription and synthesis of IL-6 and support 
the idea that IL-6 could be a marker of NB progression. Indeed, IL-6 seems to play a role in 
 9 
chemioresistance. Ara et al. has demonstrated the protective effect of IL-6 on drug-induced 
apoptosis in NB (13). Retinoic acid, currently used for NB therapy, seems to inhibit cell growth by 
down-modulation of the expression of IL-6 receptor and the secretion of IL-6 (23). Moreover, IL-6 
pathway can be targeted by the monoclonal antibody Tocilizumab used as therapy for rheumatoid 
arthritis (24). This suggests the possibility that the targeting of IL-6 pathway could be a therapeutic 
strategy also for NB. 
This article supports the role of IL-6 in NB as marker of disease progression, but additional studies 
are needed to clarify the role of the SNP rs1800795 (-174 G>C) in predicting the clinical outcome 
of patients with NB and to define its function in affecting transcription and synthesis of IL-6.  
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Table 1. Characteristics of NB patients stratified per IL-6 -176 (G>C) SNP genotype 
    Genotypic frequencies         
  n  
GG    
(%) 
GC    
(%) 
CC    
(%) 
a
P 
a
OR 
(CI=95%) 
b
P
 
 
b
OR 
(CI=95%) 
Cases 326 
176 
(0.54) 
125 
(0.38) 
25 
(0.08) 
0.24 
1.14  
(0.92-1.43) 
0.34 
1.31  
(0.75- 2.28) 
Controls 511 
295 
(0.58) 
184 
(0.36) 
32 
(0.06)     
Age 
        
 > 18 months 152 
77 
(0.50) 
63 
(0.41) 
12 
(0.08) 
0.39 
1.17  
(0.82-1.65) 
0.65 
1.22  
(0.52-2.87) 
< 18 months 168 
94 
(0.56) 
62 
(0.37) 
12 
(0.07)     
N. A.
 
 6 
       
Sex 
        
Male 178 
92 
(0.52) 
72 
(0.40) 
14 
(0.08) 
0.41 
1.16  
(0.81-1.65) 
0.52 
1.34  
(0.55–2.35) 
Female 141 
79 
(0.56) 
53 
(0.38) 
9 
(0.06)     
N. A.
 
 7 
       
INSS stage 
        
Stage 1 + 2 103 
57 
(0.55) 
44 
(0.43) 
2 
(0.02) 
c
0.21 
1.29 
(0.87-1.91) 
c
0.02 
5.03  
(1.13-22.46) 
Stage 3 + 4 192 
102 
(0.53) 
72 
(0.37) 
18 
(0.09)     
Stage 4S 23 
12 
(0.52) 
8 
(0.35) 
3 
(0.13)     
N. A.
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Risk 
    
   
 
High-risk 144 
73 
(0.51) 
55 
(0.38) 
16 
(0.11) 
0.08 
1.36  
(0.96-1.92) 
0.03 
2.51  
(1.05-5.99) 
Not high-risk 182 
103 
(0.57) 
70 
(0.38) 
9 
(0.05)     
MYCN 
        
Amplified 73 
35 
(0.48) 
32 
(0.44) 
6 
(0.08) 
0.17 
1.33  
(0.88- 2.02) 
0.33 
1.66  
(0.59-4.69) 
Not Amplified 221 
126 
(0.57) 
82 
(0.37) 
13 
(0.06)     
N. A.
 
 32               
N.A. = not available 
       ap-values and ORs from comparison of allelic frequencies  
  bp-values and ORs from comparison of genotype frequencies (GG/GC vs CC) 
c
p-values and ORs from comparison of Stage 1 + Stage 2 patients vs Stage 3 + Stage 4 
patients 
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Figure 1. Kaplan-Meier curves for OS rates. OS rates were compared between CC and any G (GC 
or CC) for the SNP IL-6 -174 in (A) all NB and (B) not MYCN amplified patients, and (C) in high-
risk NB and (D) not MYCN amplified patients. 
 
 
 
 
 
 
 
 
 
 
 
A 
P=0.004 
B 
P=0.02 
P=0.48 
D 
P=0.27 
C 
All patients All patients 
High-risk patients High-risk patients 
GG/GC 
CC 
GG/GC 
CC 
CC CC 
GG/GC GG/GC 
 16 
 
 
 
 
 
Figure 2. SNP-gene expression and IL-6 gene expression-outcome correlations. In silico and qRT-
PCR analysis of IL-6 mRNA expression in (A) 198 LCLs and (B) 31 NB tumors, respectively, 
stratified according to the SNP IL-6 -174. Kaplan-Meier analysis is shown, with individuals 
grouped by median of expression of IL-6 for OS and Progression Free Survival rates in (C and D) 
88 NB patients and (E) 102 INSS stage 4 patients with MYCN not amplified. 
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Supplementary Table 1. Characteristics of 31 neuroblastoma tumors 
  
ID 
-174 IL-6 
SNP 
genotypes 
IL-6 
mRNA 
levels 
Sex 
Age at 
diagnosis 
(months) 
INSS 
Stage 
MYCN 
status 
 1224 GG 7.56 Male 32 Stage 4 No AMP 
 1243 GG 8.08 Female 47 Stage 4 No AMP 
 1498 GG 8.65 Male 6 Stage 4 No AMP 
 1928 GG 13.52 Female 173 Stage 4 No AMP 
 1968 GG 15.28 Male 2 Stage 4 No AMP 
 2309 GG 11.51 Male 20 Stage 4 AMP 
 2372 GG 7.05 Male 80 Stage 4 No AMP 
 2388 GG 2.74 Female 36 Stage 4 No AMP 
 2397 GG 10.59 Female 7 Stage 4 No AMP 
 2437 GG 9.40 Female 45 Stage 4 No AMP 
 2484 GG 17.91 Female 6 Stage 4 No AMP 
 2576 GG 12.64 Female 32 Stage 4 No AMP 
 2578 GG 13.48 Female 23 Stage 4  Gain 
 2841 GG 12.20 Female 16 Stage 4 No AMP 
 2854 GG 15.06 Male 51 Stage 4 No AMP 
 3038 GG 15.06 Male 12 Stage 4 AMP 
 3055 GG 10.67 Male 17 Stage 4 AMP 
 1845 GC 5.99 Female 5 Stage 4 No AMP 
 2348 GC 7.08 Male 40 Stage 4 No AMP 
 2384 GC 12.00 Male 58 Stage 4  Gain 
 2568 GC 10.41 Female 35 Stage 4 No AMP 
 2599 GC 5.86 Female 48 Stage 4 No AMP 
 2622 GC 10.32 Male 49 Stage 4 No AMP 
 2633 GC 13.50 Male 37 Stage 4 No AMP 
 2692 GC 11.57 Female 116 Stage 4 No AMP 
 2852 GC 16.36 Male 50 Stage 4 Gain 
 931 CC 11.27 Female 7 Stage 4 N.A. 
 1124 CC 16.62 Male 58 Stage 4 No AMP 
 1275 CC 10.00 Female 9 Stage 4 No AMP 
 2497 CC 12.94 Male 48 Stage 4 Gain 
 2704 CC 11.68 Male 13 Stage 4 AMP 
 No AMP, not amplified; AMP, amplified 
    N.A. not available 
       
 
 
 
 
 
 
 
Supplementary Table 2. Test for independent statistical 
significance of -174 IL-6 SNP after adjustment for neuroblastoma 
risk factors 
  
Model HR (95% CI) P 
A. 
  Age (≥18 months vs <18 months)  4.18 (2.55-6.84) <0.0001 
-174 IL6 SNP (CC vs GC/GG) 1.90 (1.05-3.43) 0.03 
B. 
  MYCN (amplified vs not amplified) 3.85 (2.48-5.98) <0.0001 
-174 IL6 SNP (CC vs GC/GG) 1.95 (1.03-3.68) 0.04 
C. 
  INSS Stage (4 vs 1-2-3-4s) 9.06 (5.11-16.08) <0.0001 
-174 IL6 SNP (CC vs GC/GG) 1.90 (1.05-3.42) 0.03 
Test for independent statistical significance of -174 IL-6 SNP after 
adjustment for NB risk factors. 
HR, hazard ratio; CI, confidence interval. 
